



Universiteit
Leiden
The Netherlands

Overcoming challenges for CD3-bispecific antibody therapy in solid tumors

Middelburg, J.; Kemper, K.; Engelberts, P.; Labrijn, A.F.; Schuurman, J.; Hall, T. van

Citation

Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A. F., Schuurman, J., & Hall, T. van. (2021). Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. *Cancers*, 13(2). doi:10.3390/cancers13020287

Version: Publisher's Version






License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3209077>

Note: To cite this publication please use the final published version (if applicable).

Review

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Jim Middelburg ¹, Kristel Kemper ², Patrick Engelberts ², Aran F. Labrijn ², Janine Schuurman ²
and Thorbald van Hall ^{1,*}

¹ Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; j.middelburg@lumc.nl

² Genmab, 3584 CT Utrecht, The Netherlands; kke@genmab.com (K.K.); pen@genmab.com (P.E.); ala@genmab.com (A.F.L.); jsc@genmab.com (J.S.)

* Correspondence: T.van_Hall@lumc.nl; Tel.: +31-71-5266945

Simple Summary: CD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is currently successfully used in the clinic to treat tumors in the blood and is under investigation for tumors in our organs. The treatment of these solid tumors faces more pronounced hurdles, which affect the safety and efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of this field and identify intrinsic hurdles for solid cancers. Furthermore, we describe potential solutions and combinatorial approaches to overcome these challenges in order to generate safer and more effective therapies.

Abstract: Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.

Keywords: antibody therapy; immuno-oncology; CD3-bispecific antibody; T-cell engager; solid tumors; on-target off-tumor toxicity; T-cell co-stimulation; tumor-associated antigens



Citation: Middelburg, J.; Kemper, K.; Engelberts, P.; Labrijn, A.F.; Schuurman, J.; van Hall, T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. *Cancers* **2021**, *13*, 287. <https://doi.org/10.3390/cancers13020287>

Received: 14 December 2020

Accepted: 10 January 2021

Published: 14 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

CD3-bispecific antibodies (CD3-BsAbs) are an emerging treatment modality in the field of cancer immunotherapy. BsAbs can recognize distinct antigens with each of their antigen-binding domains, in contrast to conventional Abs that recognize the same antigen with both Fab arms. The exception is IgG4, which has been reported to naturally exchange arms to attain bispecificity [1]. CD3-BsAbs act by simultaneous binding to a tumor-associated antigen (TAA) expressed on tumor cells and to CD3 on a T cell (CD3xTAA) [2]. Crosslinking of these two cell types by CD3-BsAbs allows the formation of an immunological synapse, similar to that of a natural T-cell receptor (TCR)/peptide-major histocompatibility complex (MHC) complex [3]. This synapse results in T-cell activation and thereby the secretion of inflammatory cytokines and cytolytic molecules that are able to kill the tumor cells in the process. The strength of CD3-BsAbs lies in the fact that any T cell could serve as an effector cell, regardless of TCR specificity, as for these BsAbs, TCR signaling does not require engagement of the antigen-binding domain of the TCR, but is initiated via CD3 [4].

Therefore, CD3-BsAbs can employ all available T cells and are not limited to tumor-specific T cells, contrary to the key requirement for effective immune checkpoint therapy [5].

CD3-BsAb therapy is a passive form of immunotherapy and shows striking kinship with the adoptive cell transfer of T cells expressing chimeric antigen receptor (CAR) transgenes [6]. CARs consist of TAA binding domains from antibodies directly linked to the intracellular CD3 ζ chain and domains from costimulatory receptors (e.g., 4-1BB) and thereby activate T cells upon antigen recognition. CD3-BsAbs and CAR T cells are similar in many ways: both target a surface TAA, both exploit T-cell effector functions and both are successfully used in the clinic for hematological malignancies and show a similar type of toxicity profile [7,8]. Some disadvantages of currently clinically approved CAR T cells compared to CD3-BsAbs are: (1) patients are required to be lymphodepleted prior to infusion of CAR T cells, (2) CAR T cells have to be individually produced for each patient, whereas CD3-BsAbs can serve as off-the-shelf therapeutics, (3) CAR T cells remain in the patients after the tumor is cleared, resulting in continuous B-cell depletion in the case of CD19-targeting CAR T cells, whereas CD3-BsAbs are cleared from the blood over time and (4) unlike CD3-BsAbs, dosing cannot be adjusted to minimize adverse events [7,9]. Nevertheless, it will be important to learn from the CAR T cell field to potentially extrapolate new findings to the CD3-BsAb field.

Over the last few years, new insights in BsAb biology and enabling technologies resulted in the generation of many different formats of CD3-BsAbs, which was elaborately reviewed by Labrijn et al. [10]. As of December 2020, over 100 different CD3-BsAb formats are known, ranging from very small fragments containing two different variable domains without an Fc tail, conventional antibody structures (two Fab arms linked to an Fc tail) and larger structures with additional variable domains linked to the conventional antibody structure. These different formats determine important features, such as antibody half-life via neonatal Fc receptor (FcRn)-mediated recycling, immunogenicity, type of effector response via altered immune synapse formation and ability to penetrate in solid tumors [11]. The presence and functionality of the Fc tail determines whether the BsAb is able to bind to and activate Fc receptor (FcR)-expressing immune cells, which could lead to stronger inflammatory responses, but also allows activation of immune cells in the absence of TAA, potentially resulting in more severe adverse events (AEs) [12].

Currently, CD3-BsAbs show great potential for hematological cancers, with the FDA-approved blinatumomab (CD3xCD19) being successfully used in the clinic to treat some B-cell malignancies. Many other CD3-BsAbs are being tested in (pre)clinical studies for both hematological and solid tumors. However, contrary to the success of CD3-BsAbs in hematological malignancies, the effect of these antibodies in solid tumors is still rather limited [13]. This review will focus on essential hurdles for CD3-BsAbs for solid tumors, such as critical on-target off-tumor binding, sparse T-cell infiltration and quality of tumor-infiltrating lymphocyte (TIL) effector cells due to the presence of an immunosuppressive tumor microenvironment (TME). Lastly, we will discuss potential combination strategies to overcome these hurdles.

2. Main Text

2.1. CD3-BsAbs in Hematological Malignancies

CD3-BsAbs received a lot of attention due to their success in hematological cancers. Blinatumomab (a CD3xCD19 BsAb without an Fc tail) was FDA approved in 2014 and is now successfully used in the clinic to treat patients suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) [14]. Over 40% of adult patients treated with blinatumomab show a complete or partial response and median overall survival is improved by several months compared to standard of care chemotherapy [15–17]. Unfortunately, most patients still relapse eventually after primary response to blinatumomab therapy. These relapses are currently being extensively investigated and the data have thus far indicated that relapses are frequently found at immune-privileged

extramedullary locations and some relapses have lost CD19 antigen expression, but more research is required to further elucidate these resistance mechanisms [18,19].

Apart from blinatumomab, many other CD3-BsAbs are currently in clinical trials targeting well-established B-cell markers, like CD19, CD20, CD38 and B-cell maturation antigen (BCMA) and myeloid markers, like CD33 and CD123. For instance, in a phase I/II study, patients suffering from acute myeloid leukemia (AML) were treated with floteuzumab (CD3xCD123 BsAb) and showed promising overall response rates (complete response with full, partial or incomplete recovery of blood cells) of 30% [20]. In another phase I/II study for patients suffering from diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or follicular lymphoma (FL), epcoritamab (CD3xCD20 BsAb) therapy generated impressive responses: 44% complete response (CR) and 11% partial response (PR) for patients with DLBCL or HGBCL and 100% PR for patients with FL [21]. Comparable results were obtained with other CD3xCD20 bispecifics [22,23]. In NOD/SCID-gamma null (NSG) mice, REGN1979 (CD3xCD20) delayed tumor outgrowth better than rituximab, thereby further indicating the strength of CD3-BsAbs [24]. Interestingly, some of these trials target the same B-cell or myeloid antigens, however, with different CD3-BsAb formats. Therefore, these clinical studies could potentially inform on the role of different antibody formats' treatment safety and efficacy.

Clinical trials with blinatumomab revealed that cytokine release syndrome (CRS) is one of the major safety-related AEs [25]. The availability of CD19⁺ tumor cells and healthy B- and T cells in the same compartment allows acute and synchronic CD3-BsAb-mediated T-cell activation, followed by excessive release of inflammatory cytokines, such as IFN- γ , IL-6 and TNF- α , resulting in symptoms ranging from mild fever to multi-organ system failure [26]. However, CRS is not a specific problem for blinatumomab, but is observed for all CD3-BsAbs and CAR T-cell therapies in both hematological and solid cancer indications with CRS severities dependent on the type of therapy and target [27,28]. Preclinical research using a humanized mouse model showed that the primary mediator of CD3-BsAb-induced CRS was TNF- α produced by activated T cells, leading to massive secretion of inflammatory cytokines by monocytes [29]. The blockade of upstream TNF- α and downstream IL-1 β or IL-6 can mitigate CRS [29–31]. Others have reported that step-up dosing, or subcutaneous administration of CD3-BsAbs, decreased the extent of CRS [32,33]. Furthermore, several preclinical studies in mouse and cynomolgus monkey models showed that reducing CD3 affinity could reduce treatment-induced cytokine levels [34–37].

2.2. Historical Perspective and Current Status of CD3-BsAbs in Solid Cancers

Despite the fact that CD3-BsAbs are mostly known for their use in hematological malignancies, the first European medicines agency (EMA)-approved CD3 bispecific antibody was catumaxomab, a CD3xEpCAM BsAb for the intraperitoneal treatment of epithelial cell adhesion molecule (EpCAM)-positive malignant ascites [38]. This antibody was actually trifunctional, as its Fc was able to bind FcR-expressing cells and induced strong immunological responses [39]. Severe liver toxicity was also observed due to the activation of Kupffer cells when administered intravenously [12]. Catumaxomab was eventually withdrawn for commercial reasons in 2017, but taught the field an important lesson about the potential dangers of the presence of an active Fc in CD3-BsAbs. All current full length CD3-BsAbs in development contain Fc-silent backbones with mutations impairing the binding of Fc γ R and C1q [10]. Moreover, preclinical studies showed that Fc-silenced full length CD3-BsAbs improved T-cell trafficking towards the tumor and induced better anti-tumor responses. Wang et al. showed that CD3-BsAbs with an active Fc backbone failed to drive T cells to the tumor, but instead induced either T-cell depletion or the accumulation of T cells in the lungs [40]. This observed effect was attributed to the capacity of the Fc backbone to be bound by Fc γ R-expressing myeloid cells. Fc-silenced CD3-BsAbs did not lead to sequestration of T cells in the lungs, but they arrived in the tumor. More importantly, therapeutic efficacy was greatly improved in Fc-silenced CD3-BsAb-treated mice. A similar

trend was also observed in a syngeneic mouse model, where CD3xTrp1 (tyrosinase-related protein 1) was used to treat Trp1-positive B16F10 tumor cells [41].

As of December 2020, no CD3-BsAbs are approved for the treatment of solid tumors in the clinic. However, many different targets are being explored in clinical studies, of which most are focusing on classical TAAs, such as carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), EpCAM, HER2 and prostate-specific membrane antigen (PSMA). Other TAAs are also being explored (see Table 1 for an elaborate list). Most of these studies simply inject CD3-BsAbs, however, in some studies, these Abs piggyback with infused T cells as “bispecific-armed T cells”. Furthermore, this table also includes CD3-BsAb formats based on affinity-enhanced TCR-like domains that recognize peptide–human leukocyte antigen (HLA) complexes (immune mobilizing monoclonal T-cell receptors against cancer (ImmTACs)) [42]. Multiple other TAAs are currently pursued in preclinical studies hoping to make their way to the clinic, including B7-H4, CD133, CD155, claudin 6 (CLDN6), cellular mesenchymal to epithelial transcription factor (C-MET), ephrin receptor A10 (EphA10), folate receptor 1 (FOLR1), HLA-A*24: survivin 2B₈₀₋₈₈, integrin β4 (ITGB4), P-cadherin, prolactin receptor (PRLR), receptor tyrosine kinase-like orphan receptor 1 (ROR1), TNF-related apoptosis-inducing ligand receptor (TRAIL-R2), transferrin receptor (TfR) and tumor-associated calcium signal transducer 2 (Trop-2) [43–69].

Table 1. Overview of clinical studies involving CD3-BsAbs targeting solid tumors.

TAA	Disease	Phase
Completed Clinical Trials		
CEA	CEA-positive tumors	Phase I (NCT02324257, completed)
CEA	Gastrointestinal adenocarcinomas	Phase I NCT01284231, completed)
CEA	Advanced CEA-positive solid tumors	Phase I (NCT02291614, completed)
CEA	Advanced CEA-positive solid tumors	Phase I (NCT02650713, completed)
EGFR	Brain and central nervous system tumors	Phase I (NCT00005813, completed)
EpCAM	Solid tumors	Phase I (NCT00635596, completed)
EpCAM	Ascites, ovarian cancer, fallopian tube cancer, peritoneal cancer	Phase II (NCT00326885, completed)
EpCAM	Ovarian cancer, fallopian tube cancer, peritoneal cancer	Phase II (NCT00377429, completed)
EpCAM	Recurrent ovarian cancer, fallopian tube cancer, peritoneal carcinomatosis	Phase II (NCT01815528, completed)
EpCAM	Ovarian cancer, fallopian tube cancer, peritoneal cancer	Phase II (NCT01246440, completed)
EpCAM	Ovarian cancer	Phase II (NCT00563836, completed)
EpCAM	Ascites, carcinoma, epithelial cancer	Phase II (NCT01065246, completed)
EpCAM	Ovarian cancer, gastric cancer, pancreatic cancer, malignant ascites	Phase II (2005-001700-39, completed)
EpCAM	Gastric cancer and gastric adenocarcinoma	Phase II (NCT00352833, completed)
EpCAM	Peritoneal carcinomatosis and gastric adenocarcinoma	Phase II (NCT01504256, completed)
EpCAM	Ovarian cancer, fallopian tube cancer, peritoneal cancer	Phase II (NCT00189345, completed)
EpCAM	Gastric cancer and gastric adenocarcinoma	Phase II (NCT00464893, completed)
EpCAM	Malignant ascites and EpCAM-positive tumors	Phase II/III, (NCT00836654, completed)
EpCAM	EpCAM-positive solid cancers	Phase III (NCT00822809, completed)
GD2	Neuroblastoma	Phase I (NCT00877110, completed)
gpA33	Colorectal carcinoma	Phase I (NCT02248805, completed)
GPC3	Solid tumors	Phase I (NCT02748837, completed)
HER2	Breast cancer, metastatic breast cancer	Phase I (NCT00027807, completed)
HLA-A*02:01:gp100	Melanoma, advanced melanoma	Phase I (NCT01209676, completed)
HLA-A*02:01:gp100	Malignant melanoma	Phase I (NCT01211262, completed)
PSMA	Prostate cancer	Phase I (NCT02262910, completed)
PSMA	Prostatic neoplasms	Phase I (NCT01723475, completed)

Table 1. Cont.

TAA	Disease	Phase
Active clinical trials *		
5T4	Malignant solid tumors	Phase I/II (NCT04424641, recruiting)
B7-H3	Advanced solid tumors, metastatic solid tumors	Phase I (NCT03406949, active not recruiting)
CEA	Colorectal cancers	Phase I (NCT03866239, recruiting)
CEA	NSCLC	Phase I/II (NCT03337698, recruiting)
CEA, EGFR, GPC3, HER2, MUC1	Malignant solid tumors	Phase I (NCT04076137, recruiting)
CEA, EpCAM, GPC3, MUC1	Advanced liver cancer	Phase II (NCT03146637, recruiting)
CLDN18.2	Gastric and gastroesophageal junction adenocarcinoma	Phase I (NCT04260191, recruiting)
DLL3	Small cell lung carcinoma	Phase I (NCT03319940, recruiting)
DLL3	Small cell lung cancer, advanced cancers	Phase I/II (NCT04471727, not yet recruiting)
EGFR	Multiple solid gastrointestinal tumors	Phase I (NCT01420874, active not recruiting)
EGFR	Glioblastoma multiforme, gliosarcoma	Phase I (NCT03344250, recruiting)
EGFR	Pancreatic cancer	Phase I (NCT04137536, recruiting)
EGFR	Advanced pancreatic cancer	Phase Ib/II (NCT02620865, active not recruiting)
EGFR	Advanced and metastatic pancreatic adenocarcinoma	Phase Ib/II (NCT03269526, recruiting)
EGFRv3	Glioblastoma multiforme, malignant glioma	Phase I (NCT03296696, active not recruiting)
EpCAM	Large bowel (colon) cancer, colorectal cancer	Phase U (ChiCTR-ROC-16008620, not yet recruiting)
EpCAM	Malignant ascites, advanced solid tumors	Phase I (CTR20181212, recruiting)
EpCAM	Ascites, advanced solid tumors	Phase I (ChiCTR1900024144, recruiting)
EpCAM	Malignant ascites	Phase I (NCT04501744, recruiting)
EpCAM	Gastric adenocarcinoma, peritoneal carcinomatosis, colorectal adenocarcinoma	Phase II (2010-022810-26, recruiting)
EpCAM	Advanced gastric cancer, stomach cancer, gastric cancer	Phase III (NCT04222114, recruiting)
GD2	Neuroblastoma	Phase I (NCT02650648, active not recruiting)
GD2	Neuroblastoma, osteosarcoma, other solid tumors	Phase I/II (NCT03860207, recruiting)
GD2	Neuroblastoma, osteosarcoma	Phase I/II (NCT02173093, recruiting)
gpA33	Metastatic colorectal cancer	Phase I/II (NCT03531632, active not recruiting)
GPC3	Advanced solid tumors, recurrent solid tumors	Phase I (JapicCTI-194805, recruiting)
GUCY2C	Gastrointestinal malignancies, esophageal cancer	Phase I (NCT04171141, recruiting)
HER2	Breast cancer	Phase U (ChiCTR-ROC-16008650, not yet recruiting)
HER2	HER2-positive solid tumors	Phase I (NCT04501770, recruiting)
HER2	Breast cancer and leptomeningeal metastases	Phase I (NCT03661424, recruiting)
HER2	Esophageal, gastric, pancreatic, liver, gallbladder and bowel cancer	Phase I (NCT02662348, unknown status)
HER2	Advanced solid tumors	Phase I (NCT03448042, recruiting)
HER2	Advanced solid tumors	Phase I (CTR20171194, recruiting)
HER2	Solid tumors, advanced solid tumors	Phase I (ChiCTR1900024128, recruiting)
HER2	Breast cancer	Phase I/II (NCT03983395, recruiting)
HER2	Metastatic breast cancer	Phase I/II (NCT03272334, recruiting)
HER2	Metastatic castration resistant prostate cancer	Phase II (NCT03406858, status unknown)
HER2	Breast cancer	Phase II (NCT01147016, status unknown)
HER2	Breast cancer	Phase II (NCT01022138, status unknown)
HLA-A*02:01:gp100	Uveal melanoma	Phase I/II (NCT02570308, active not recruiting)
HLA-A*02:01:gp100	Melanoma	Phase I/II (NCT02535078, active not recruiting)

Table 1. Cont.

TAA	Disease	Phase
HLA-A*02:01:gp100	Uveal melanoma, metastatic uveal melanoma, advanced uveal melanoma	Phase II (NCT03070392, active not recruiting)
HLA-A*02:MAGE-A4	Advanced solid tumors, metastatic solid tumors	Phase I/II (NCT03973333, recruiting)
MSLN	Mesotheliomas, ovarian cancers, pancreatic cancers	Phase I/II (NCT03872206, recruiting)
MUC16	Ovarian cancer fallopian tube cancer, peritoneal cancer	Phase I/II (NCT04590326, not yet recruiting)
MUC16	Ovarian cancer fallopian tube cancer, peritoneal cancer	Phase I/II, (NCT03564340, recruiting)
MUC17	Gastric and gastroesophageal junction cancer	Phase I (NCT04117958, recruiting)
NY-ESO1	NY-ESO1-positive tumors	Phase I/II (NCT03515551, recruiting)
PRAME	Advanced solid tumors, cancer indications	Phase I/II (NCT04262466, recruiting)
PSCA	NSCLC, breast cancer, pancreatic cancer, urogenital cancer	Phase I NCT(03927573, recruiting)
PSMA	Prostate cancer	Phase I (NCT04077021, recruiting)
PSMA	Prostate cancers, advanced solid tumors, neoplasms, renal cancers, small cell lung cancer	Phase I (NCT03926013, recruiting)
PSMA	Castration-resistant prostate carcinoma	Phase I (NCT04104607, recruiting)
PSMA	Metastatic castration-resistant prostate cancer	Phase I (NCT03792841, recruiting)
PSMA	Squamous cell lung carcinoma	Phase I/II NCT04496674, not yet recruiting)
PSMA	Prostate cancer	Phase I/II (NCT03577028, recruiting)
SSTR2	Neuroendocrine tumors and gastrointestinal neoplasms	Phase I (NCT03411915, recruiting)
SSTR2	Merkel cell carcinoma and small cell lung cancer	Phase I/II (NCT04590781, not yet recruiting)
STEAP1	Metastatic castration-resistant prostate cancer	Phase I (NCT04221542, recruiting)

* Data as of 13 November 2020. Clinical studies are ordered based on the targeted tumor-associated antigen (TAA). CEA, carcinoembryonic antigen; CLDN18.2, claudin18 isoform 2; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor, EpCAM, epithelial cell adhesion molecule; GD2, disialoganglioside; gp100, glycoprotein 100; gpA33, glycoprotein A33; GPC3, glypican 3; GUCY2C, guanylyl cyclase C; HER2, human epidermal growth factor receptor 2; HLA, human leukocyte antigen; MAGE-A4, melanoma-associated antigen 4; MSLN, mesothelin, MUC16, mucin 16; NSCLC, non-small cell lung cancer; NY-ESO1, New York esophageal squamous cell carcinoma 1; PRAME, preferentially expressed antigen in melanoma; PSCA, prostate stem cell antigen; PSMA, prostate-specific membrane antigen; SSTR2, somostatin receptor 2; STEAP1, six-transmembrane epithelial antigen of the prostate 1.

Most of these studies are currently still enrolling patients and we are only starting to get a view on CD3-BsAb therapy safety and efficacy in solid cancers. First, in three different studies, patients were treated with an i.p. infusion of catumaxomab, which resulted in frequent but manageable toxicities and increased time between paracentesis in all studies and even a significant improvement in overall survival (OS) in one study [38,70,71]. Other clinical trials in solid tumors reported dose-limiting toxicities (DLTs) for CD3-BsAbs targeting CEA, EpCAM and HLA-A*02:01:gp100 [70–73]. These toxicities consisted of abnormal liver parameters, colitis, CRS, diarrhea, dyspnea, hypotension, hypoxia, respiratory failure and tachycardia. Some of these toxicities were caused by tumor lesion inflammation, however, most were reversible upon treatment discontinuation. Responses to CD3-BsAbs varied from only 1.5% partial response (PR) [70], up to 15% PR and 46% stable disease (SD) [73] and everything in between [73–75]. Pasotuxizumab, a CD3-BsAb targeting PSMA, obtained the most impressive results with two long-term responders, of which one had marked regression of soft tissue and bone metastases [74]. Overall, some evidence for efficacy induced by CD3-BsAbs in solid tumors has been found, however, with only a handful of long-term survivors, some partial responses and the occurrence of multiple DLTs, the development of CD3-BsAbs in solid tumors lags behind that in hematological malignancies.

2.3. Hurdles in Solid Tumors

The observation that CD3-BsAbs seem more efficacious in hematological malignancies than in solid tumors can be attributed to several challenges that are specific to solid tumors. The first hurdle is on-target off-tumor toxicities, as these seem less forgiving for TAAs selected for solid tumor targeting, when compared to hematologic TAAs [76]. In the case of hematological cancers, the temporary depletion of B cells or myeloid subsets is reversible,

as long as hematopoietic stem cells are not targeted, allowing replenishment of the blood pool. However, solid tumor TAAs are often also expressed on tissues of healthy organs, which can lead to immune pathology and organ failure with potential fatality, as shown in a preclinical mouse study using a CD3-BsAb targeting EGFR [75]. Critical selection of a tumor-specific TAA is thus crucial.

The second hurdle is the availability of effector cells in the TME. For hematological malignancies, cancer cells in the blood are surrounded by T cells, allowing the CD3-BsAb to draw from an endless pool of effector cells, whereas solid tumors require T-cell infiltration for therapeutic efficacy. In this context, three immune landscapes have been described: (1) “inflamed” tumors, which are infiltrated by immune cells and frequently respond to immune checkpoint therapy [77], (2) “immune desert” tumors, which have a reduced or absent immunogenicity, resulting in very few primed tumor-specific T cells that home to the tumor [78] and (3) “immune-excluded” tumors, which display T-cell infiltration in the stroma, but not the tumor nests [79,80]. For these immune-excluded tumors, the deposition of extracellular matrix (ECM) components in the stroma results in a physical barrier surrounding the tumor parenchyma. Apart from this physical barrier, the secretion of soluble factors such as transforming growth factor beta (TGF- β) and C-X-C motif chemokine ligand 12 (CXCL12) further frustrates T-cell infiltration. Since T-cell trafficking to solid tumors can be scarce in immune desert or immune-excluded tumors, CD3-BsAbs might have only a few T cells available in the TME (see Scheme 1 for T-cell development and trafficking). The requirement of T-cell infiltrate for effective CD3-BsAb therapy was described by Ströhlein et al. in a clinical study with catumaxomab [81].

T cells originate in bone marrow and progenitor stem cells are educated in the thymus, where they mature and undergo positive and negative selection, to largely exclude “self-reactivity” and release non-self-specific T cells [82]. After this education, the newly formed naïve T cells remain in the peripheral blood and lymph system via the expression of chemokine receptor type 7 (CCR7) and lymph node-produced cognate C-C chemokine ligand 19 (CCL19)/CCL21, in addition to the sphingosine-1-phosphate (S1P) system [83,84]. After activation by dendritic cells (DCs), T cells differentiate into effector cells and different types of memory cells. T cells lose CCR7 expression after this priming event, while they gain expression of other chemokine receptors, such as C-X-C chemokine receptor type 3 (CXCR3) [85]. This enables them to follow chemokine gradients of C-X-C motif chemokines like CXCL9 and CXCL10 towards inflamed tissues, which they enter via selectin/integrin-mediated intravasation [86]. T cells are retained in tissues to clear pathogens and tumors by the expression of retention integrins such as CD103 [87]. Central memory T cells regain CCR7 and recirculate in blood and lymph nodes, whereas effector memory T cells and tissue-resident memory T cells are still able to enter and reside in tissues [88].

Scheme 1. Explanation about T cell development and trafficking [82–88].

The third and final hurdle concerns the quality of infiltrating T cells. TILs can be dysfunctional, with impaired ability to proliferate and produce cytolytic molecules, including granzymes and perforins [89]. Immunosuppressive cells in the TME, including cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells (MDSCs) and regulatory T cells (T_{regs}) produce factors such as TGF- β , IL-10, indoleamine 2,3-dioxygenase (IDO) and arginase, which hamper T-cell metabolism and activation [90]. Additionally, effector T cells were shown to exhibit an “exhausted” profile due to chronic antigen stimulation, as witnessed by the expression of inhibitory immune checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) [91]. Furthermore, it has been reported that CD3-BsAbs might induce TIL apoptosis via activation-induced cell death, which hampers a strong anti-tumor response [48]. Some of the discovered TME obstacles have only been described in resistance upon immune checkpoint therapy, however, we expect these hurdles to also play a role in CD3-BsAb therapy. An overview of these hurdles is shown in Figure 1.




Figure 1. Three main hurdles for CD3-BsAb therapy in solid tumors. (1) CD3-BsAbs can generate on-target off-tumor toxicities by binding with the TAA arm to the same antigen on healthy cells, thereby redirecting T cells towards normal tissues, resulting in permanent tissue destruction. (2) Certain types of solid tumors (“immune desert” and “immune-excluded”) have sparse or even no T-cell infiltration, thereby preventing CD3-BsAb from cross-linking T cells to tumor cells, resulting in limited treatment efficacy. (3) The tumor microenvironment (TME) of solid tumors contains multiple immunosuppressive cell types, including cancer-associated fibroblasts, regulatory T cells and tumor-associated macrophages, thereby hampering the quality of effector T cells. Furthermore, immune checkpoints further decrease tumor-infiltrating lymphocyte (TIL) effector functions.

2.4. Solutions and Opportunities

2.4.1. Mitigating of On-Target Off-Tumor Toxicities

Most alterations in cells during the process of oncogenesis affect intracellular circuits involved in the cell cycle, survival and invasive growth [92]. As such, the surface proteome is relatively conserved between cancer cells and their healthy counterparts, with the exception of tyrosine kinase growth receptors, e.g., EGFR family members, which are overexpressed and sometimes truncated in extracellular domains [93]. The search for suitable TAAs for targeting by CD3-BsAbs is therefore complicated, as these targets should be surface proteins that are exclusively expressed by tumor cells and absent in healthy cells. HLA molecules can present small neo-antigenic peptides derived from mutated proteins or peptides from tumor virus proteins and these peptide/HLA complexes can serve as highly cancer-specific TAAs [94]. Their disadvantage is that most identified neoantigens are patient specific and viral antigens are observed in only a subset of cancers [95,96]. A lot of research is currently being performed to identify new and more common neoantigens, which may result in promising future TAAs for CD3-BsAb therapy [97]. The next best targets are overexpressed proteins on tumor cells compared to healthy cells, which is the case for most of the clinically targeted TAAs, such as CEA, EGFR, EpCAM and HER2 [98,99]. Targeting these TAAs offers some selectivity of tumor cells over healthy cells dependent on the extent of overexpression, however, healthy tissues can still be affected.

Some of the most differentially expressed genes in cancer are actually intracellular proteins, which cannot be reached by conventional antibodies [100]. This intracellular proteome is only approachable via HLA class I molecules, which present them to the outer world. These surface peptide/HLA complexes can be targeted with peptide-specific antibody formats or by TCR molecules, such as ImmTACs or T-cell engaging receptor (TCER) molecules [101,102]. The TCR arms of ImmTACs and TCERs are affinity enhanced to low nM ranges to obtain sufficient TAA binding strength to the cancer cell in order to successfully engage effector T cells with the CD3-binding arm. However, major disadvantages of TCR-like CD3-BsAbs are HLA restrictions and vulnerability towards HLA downregulation in the tumor. ESK1, an ImmTAC recognizing intracellular Wilms' tumor 1 (WT1) antigen presented in HLA-A*02:01, was able to lyse WT1-positive tumor cells in vitro and reduce tumor outgrowth of AML, ALL and mesothelioma tumors in NSG mice [103]. A clinical trial with the ImmTAC tebentafusp targeting gp100 presented on HLA-A2*02:01 has successfully been completed and response rates of 15% PR and 46% SD were reported. Unfortunately, DLTs in the form of hypotension were observed in four patients receiving the highest dose [73]. These intracellular targets are both overexpressed TAAs and still seem to generate on-target off-tumor toxicity (as described for tebentafusp). The development of ImmTACs targeting more specific TAAs, such as neoantigens derived from highly conserved Ras mutations in various cancers, E6 and E7 peptides from human papilloma virus (HPV)-induced cancers or T-cell epitopes associated with impaired peptide processing (TEIPP) antigens for cancers with defects in transport associated with antigen processing (TAP) function, could be promising [104–106].

To improve tumor selectivity and specificity and mitigate on-target off-tumor toxicities, the TAA avidity could be increased, for instance, by generating so-called 2:1 CD3-BsAbs. These 2:1 CD3-BsAbs contain a second TAA binding fragment, resulting in a CD3xTAAxTAA bispecific antibody [107]. Slaga et al. showed that specificity for high-expressing HER2 cells was significantly increased when using a 2:1 HER2-targeting CD3-BsAb in vitro [108]. More importantly, tumor growth of high HER2-expressing tumors in NSG mice was efficiently delayed by the 2:1 CD3-BsAb, whereas no anti-tumor efficacy was observed in low HER2-expressing tumors. In contrast, the 1:1 CD3-BsAb was able to effectively delay tumor growth in both high and low HER2-expressing tumors (used here as a model for healthy tissue). In cynomolgus monkeys, i.v. infusion of the 2:1 CD3-BsAB did not result in an increase in C-reactive protein (CRP), T-cell activation or alanine or aspartate aminotransferase (ALT and AST) levels in blood upon exposure to the endogenous expression of HER2 on healthy cells. However, a direct comparison between these two formats was not feasible, as similar cynomolgus monkey data were not generated for the 1:1 CD3-BsAb. A similar improved selectivity was observed for a 2:1 CEA-targeting CD3-BsAb [109]. This CD3-BsAb was tested in patients with advanced CEA-positive carcinomas and displayed signs of anti-tumor effects (5% PR, 11% SD) with a manageable toxicity profile, which was most likely associated with tumor lesion inflammation [72]. In this 2:1 format, TAA affinity plays a very important role: when the TAA affinity is too high, there is no increased specificity, as the BsAb can still bind to low levels of the TAA expressed on healthy cells. On the other hand, if the TAA affinity is too low, the potency of the CD3-BsAb will be compromised. Therefore, modulating TAA affinity could be seen as a tight balance between specificity and efficacy [110]. In a similar fashion, specificity could also be improved for 1:1 CD3-BsAbs by lowering TAA affinity, however, due to the lower avidity compared to 2:1 BsAbs, it is expected to be harder to achieve the optimal balance [111].

A conceptual novelty in this area is the generation of CD3-BsAbs as prodrugs that are activated in the TME. Differences in physiological features, such as hypoxia-related low pH, excessive production of ECM and increased proteolysis, distinguish solid tumors from healthy tissues [112,113]. These differences warranted the development of CD3-BsAbs with binding regions that are masked with protease-cleavable linkers. Boustany et al. developed a masked CD3xEGFR BsAb, which blocked both CD3 and EGFR binding [114]. The binding

of this BsAb to CD3 and EGFR was strongly reduced *in vitro* in the absence of proteases, whereas *in vivo* anti-tumor efficacy was retained. In cynomolgus monkeys, the maximum tolerated dose (MTD) for masked CD3xEGFR was 60-fold higher than the unmasked variant. Additionally, the masked variant greatly prolonged plasma concentrations at higher dosing concentrations. Very recently, Panchal et al. described the development of conditional bispecific-redirected activation (COBRA) T-cell engagers [115]. This format separates the α -CD3 V_H and V_L via a matrix metalloproteinase 9 (MMP9)-degradable linker, thereby only allowing CD3 binding after linker cleavage, while constantly allowing EGFR and serum albumin binding (to increase half-life). In co-cultures of T cells with tumor cell lines, a dependency on the presence of MMP9 was demonstrated for T-cell-mediated cytotoxicity. *In vivo*, COBRA BsAb could completely eradicate established HT-29 colorectal tumors in NSG mice, whereas their non-cleavable BsAb counterpart displayed no anti-tumor activity. Furthermore, Geiger et al. described a folate receptor 1 (FOLR1)-targeting CD3-BsAb (Prot-FOLR1-TCB) that linked a protease-cleavable anti-idiotypic anti-CD3 mask to the CD3 arm [116]. This masked the CD3-binding domain of the BsAb and was cleaved by proteases produced in the TME, resulting in selective T-cell activation after the addition of protease *in vitro*. In humanized mice, Prot-FOLR1-TCB was able to delay tumor outgrowth to a similar extent to the non-masked BsAb. Other approaches that have split the anti-CD3 modality into two separate components, which only functionally recombine at the tumor surface when both bind to separate TAAs, are also being explored [117,118].

Another way to mitigate on-target off-tumor toxicities is to alter CD3-BsAb distribution, for example, by the modification of CD3 affinity. In a preclinical mouse study, the distribution of radiolabeled CD3xHER2 BsAbs with different CD3 affinities was followed by single-photon emission computed tomographic (SPECT) imaging. This study showed that CD3-BsAbs with a high affinity CD3 arm accumulated in T-cell-rich tissues, such as the spleen and lymph nodes, whereas CD3-low affinity BsAbs accumulated mainly in the HER2⁺ tumor, thereby affecting the biodistribution and treatment outcome [119]. Instead of the systemic administration of (conditionally active) CD3-BsAb, another option to alter distribution could be to administer CD3-BsAbs intratumorally. Although this would not completely prevent systemic spreading, as some CD3-BsAb will probably enter the blood by diffusion, local administration can strongly reduce on-target off-tumor toxicity [120]. Although local administration is possible under ultrasound guidance for non-superficial tumors, this method is still complicated because multiple injections are required. Alternatively, delivery systems can be exploited that would selectively release or produce CD3-BsAb in the tumor. One such method is the use of transduced (tumor-specific) T cells, that are engineered to express CD3-BsAbs upon T-cell activation, also called the secretion of T-bsAbs by engineered (STAb)-T cells [121]. Iwahori et al. generated STAb-T cells recognizing the erythropoietin-producing hepatocellular carcinoma A2 (EphA2) antigen that produced CD3xEphA2 BsAb upon T-cell activation [122]. They showed effective anti-tumor activity in U373 glioma and A549 lung tumors in NSG mice, while systemic exposure to the CD3-BsAb seemed to be minimal, as indicated by the absence of human cytokines in peripheral blood. Alternatively, BsAb constructs can be expressed in producer lines or non-specific T cells, however, this approach is not well developed at the moment [123,124]. Oncolytic virus (OV) was also used as a delivery vehicle as it selectively replicates in transformed cancerous cells over healthy cells [125]. Fajardo et al. described an oncolytic adenovirus encoding CD3xEGFR BsAb and observed a modest but significant delay in tumor outgrowth when used either by intratumoral or *i.v.* administration in NSG mice [126]. In a different study, oncolytic measles virus encoding CD3xCEA BsAb was developed and used to treat patient-derived colorectal cancer xenografts in NSG mice [127]. Tumor outgrowth was moderately delayed in mice treated intratumorally, without detectable BsAb in serum. However, when mice were treated *i.v.*, only low BsAb levels were detected in the tumor in contrast to high BsAb concentrations in peripheral blood. Other groups also used OVs encoding CD3-BsAbs targeting EpCAM, Eph-A2 and CD44v6 and observed anti-tumor activities against several tumor models [128–130]. However, in all of

these studies, OV encoding CD3-BsAb was administered locally and toxicity evaluation was not reported. An overview of mitigation strategies to overcome off-tumor on-target toxicities is depicted in Figure 2.




Figure 2. Solutions to mitigate hurdle 1: on-target off-tumor toxicities. (1) Target TAAs that are exclusively expressed by tumor cells, such as human leukocyte antigen (HLA)-presented neo-antigens, or surface antigens from virally induced cancers. (2) The avidity for TAAs can be increased with formats that include multiple TAA binding arms. This results in increased selectivity for tumor targeting over healthy tissues. (3) Binding arms of CD3-BsAbs can be masked using a protease-cleavable linker, making the BsAb only active inside the tumor. In healthy tissues, a minimal presence of proteases limits unmasking of the CD3 arm, whereas the abundance of matrix metalloproteinases (MMPs) in the TME allows the CD3-BsAb to redirect T cells towards the tumor. (4) Ensure local delivery of CD3-BsAbs to decrease systemic exposure by either local injection, or using delivery systems that locally produce these BsAbs, such as oncolytic viruses (OVs) and STAb-T cells.

2.4.2. Increasing the Number of Intratumoral T cells

Tumors can be classified in three categories regarding T-cell infiltration: immune desert, immune-excluded and inflamed [79]. Immune desert tumors barely contain T cells at all, not in the tumor nests nor surrounding the rims, thereby potentially limiting CD3-BsAb therapy efficacy. Interestingly, intratumoral OV administration can ignite T-cell influx in immune desert tumors. The replication of oncolytic virus can generate an interferon response in the TME and induce an innate and adaptive antiviral immune response [131–133]. We used this concept to pre-treat immune desert murine tumors (B16F10 melanoma and (LSL-Kras^{G12D}, LSL-Trp53^{R172H}, Pdx-1-Cre) KPC pancreatic carcinoma) with OV, which induced sensitization and generated major T-cell influx peaking around day 7, allowing strong tumor regression upon CD3-BsAb treatment [134]. In the absence of OV sensitization, CD3-BsAb did not even delay tumor growth, underlining the importance of an inflammatory TME. Of note, we found that the simultaneous administration of CD3-BsAb and OV did not provide survival benefit, indicating that the timing of OV and CD3-BsAb is an important aspect.

Immune-excluded tumors have T cells surrounding the tumor, but penetration into tumor beds is hindered by physical barriers or soluble factors. Efforts to improve therapy efficacy in these types of tumors should therefore focus on removing these obstructions. The physical barrier is mainly formed by ECM structures, which forces T cells to move along areas of increased stiffness instead of following the chemokine gradient in a process called haptotaxis [135]. This barrier consists of proteoglycans and fibrous proteins such as collagen, elastin and laminin, which are mainly produced by CAFs, but also by tumor cells and stellate cells [135,136]. The ECM could be targeted by the direct destruction of ECM

components, such as collagen and hyaluronic acid (HA), a process which is also studied in the context of chemotherapeutic drug delivery to the tumor [137–139]. Guan et al. used hyaluronidase to break down HA, which increased the infiltration of tumor-specific T cells and greatly improved treatment efficacy in a B16.OVA melanoma mouse model [140]. Not only ECM components, but also their cellular producers could be targeted. CAFs are the major producers of ECM products and highly express fibroblast activation protein (FAP), which constitutes an attractive target for immunotherapy. In several mouse tumor models, T-cell infiltration was increased upon CAF targeting using DNA vaccines or fibrosis inhibitors [141–143]. OV encoding a CD3-BsAb targeting FAP was elegantly used in several studies to kill CAFs and simultaneously enhance T-cell infiltration [144–146].

Apart from creating a physical barrier, CAFs can also influence T-cell infiltration by various secreted molecules [147]. CAFs are the major source of the chemokine CXCL12, which has been implicated to mediate T-cell exclusion in solid tumors [148]. The inhibition of CXCL12 or its receptor CXCR4 resulted in increased T-cell infiltration and rendered tumors vulnerable towards checkpoint inhibition therapy in mouse models for pancreatic and colorectal cancer [148,149]. Furthermore, TGF- β has been implicated in hampering T-cell infiltration. This immunosuppressive cytokine is produced by CAFs, but also many other cells, including T_{regs} and M2 macrophages [147]. Similar to CXCL12 signaling inhibition, blocking TGF- β signaling resulted in more T-cell infiltration and increased sensitivity to checkpoint inhibition therapy in multiple mouse models for breast cancer and colorectal cancer [150–152]. Post-translational modifications of secreted factors in the TME can also affect T-cell attraction, as was reported for CCL2 [153]. Nitrosylation of CCL2 by reactive nitrogen species (RNS) in the TME resulted in T cells being stuck in the stroma surrounding the tumor cells. The inhibition of RNS production greatly improved T-cell infiltration in several mouse tumor models and thereby improved survival as a monotherapy or in combination with adoptive cell transfer. An overview of solutions to overcome sparse T-cell infiltration is shown in Figure 3.




Figure 3. Solutions for hurdle 2: sparse T-cell infiltration. (1) Pre-treatment with OV generates a strong interferon response in the tumor, resulting in local innate and adaptive immune responses and strong T-cell infiltration. (2) Disruption of the physical extracellular matrix (ECM) barrier prevents T cells from getting stuck in the ECM and allows infiltration into the tumor nests. (3) Targeting cancer-associated fibroblasts (CAFs) removes the major producers of ECM components and immune-excluding cytokines, thereby improving T-cell infiltration. (4) Blockade of immune-excluding cytokines reduces limiting factors for T-cell infiltration, resulting in better infiltrated tumors.

2.4.3. Improving the Quality of T-cell Responses

When the CD3-BsAb and sufficient T cells have finally reached the tumor, they are faced with another challenge: a hostile and immunosuppressive TME. Firstly, immune checkpoint ligands are known to be expressed in the TME, such as programmed death ligand 1 (PD-L1) and HLA-E [154,155]. PD-L1 is upregulated on tumor, stromal and immune cells upon local interferon release by immune cells [156–158]. Most intratumoral T cells already express PD-1 and the CD3-BsAb-mediated activation of T cells further stimulates the expression of this inhibitory co-receptor, thereby hampering effector functions and treatment efficacy [159,160]. Combination therapies of CD3-BsAbs and checkpoint blockade have been widely investigated in multiple in vitro studies and mouse models and resulted in improved tumor control [44,161,162]. Interestingly, Osada et al. reported that PD-1/PD-L1 blockade could not improve T-cell functioning in an in vitro setting if blockade is applied after T cells have engaged tumor cells [163]. Exhausted cells could no longer be rescued when blockade was applied too late, thereby emphasizing the importance of timing. The combination of CD3-BsAbs with checkpoint blockade is also being explored in several clinical studies (NCT03319940, NCT03531632, NCT03406858, NCT03272334, NCT03564340, NCT03792841, NCT04590781 and NCT02324257). The NCT02324257 study (CD3xCEA in combination with atezolizumab (anti-PD-L1) for patients with advanced CEA-positive tumors) has been completed and seemed to be in line with previous preclinical results: the combination of CD3-BsAbs with checkpoint blockade showed better anti-tumor responses when compared to CD3-BsAb monotherapy and they found no evidence of increased toxicities [72]. Therefore, this combination holds great promise.

Unfortunately, not only immune checkpoints have the capability to dampen T-cell function. Due to their rapid glycolysis-dependent proliferation, tumor cells generate a hypoxic and low-glucose TME [164]. In these hypoxic conditions, hypoxia-induced factors (HIFs) initiate the expression of CD39 and CD73 by multiple cell types in the TME; CD39 and CD73 convert free ATP in the TME into adenosine [165]. Adenosine has been reported to counteract TCR activation by binding to adenosine A_{2A} receptors via protein kinase A and cyclic Amp signaling, which suppresses the effector functions of T cells [161,162]. Furthermore, low glucose concentrations have been reported to dampen the anti-tumoral cytokine production and survival of effector T cells, as they rely heavily on glucose for their functioning [166,167]. Apart from these tumor-mediated factors, stromal cells, infiltrating T_{regs} and MDSCs secrete other immunosuppressive factors, such as IDO, TGF- β , IL-10 and arginase. IDO has been reported to degrade the amino acid tryptophan into kynurenine, resulting in decreased effector function via downregulation of the CD3 ζ -chain, and induce apoptosis in T cells [164,168]. TGF- β is able to suppress T-cell effector function and inhibit the differentiation of CD4⁺ cells into effector cells, while promoting T_{reg} differentiation [169–171]. IL-10 has been described to induce T-cell anergy and prevent the development of new effector T cells by decreasing antigen presentation and costimulation on antigen-presenting cells (APCs) [172,173]. Arginase breaks down the amino acid arginine and, similar to IDO, results in the downregulation of the CD3 ζ -chain and thereby decreased cytotoxic and proliferative capacity of T cells [174,175].

Most of these immunosuppressive factors do not only act on T cells but also on other cells in the TME to generate a negative feedback loop and dampen the inflammatory response. The inhibitory effect on T cells could be overcome by decreasing the amount of immunosuppressive signals, which could be accomplished by blocking receptor–ligand interactions for these molecules. Several studies have been published reporting improved T-cell effector function after blocking adenosine, arginase, IDO, IL-10 and TGF- β [176–181]. CD3-BsAb therapy has thus far only been combined preclinically with IDO blockade. Hong et al. showed improved in vitro killing and in vivo tumor control of EpCAM- and IDO-positive murine breast cancer cells using a combination of an EpCAMxCD3 BsAb with IDO blockade [182]. The cells producing these immunosuppressive factors can also be targeted, which is already being extensively studied for CAFs, as described above. MDSCs are popular targets as well, with therapies being developed to deplete them and

prevent migration into the TME, resulting in improved anti-tumor activity in combination with several different types of immunotherapy [183–190]. Currently, no combinations of CD3-BsAbs and MDSC targeting have been reported for solid tumors. However, several studies in hematological malignancies showed that CD3xCD33 BsAbs mediated both AML and MDSC killing, yielding promising treatment outcomes [191,192]. Finally, depleting T_{regs} in combination with CD3-BsAb treatment could be favorable in two ways: (1) T_{regs} secrete immunosuppressive cytokines such as IL-4, IL-10 and TGF- β and, more importantly, (2) T_{regs} are suggested to be activated by CD3-BsAbs, resulting in a dampened treatment effect [193,194]. Forkhead box protein P3 (FoxP3)-positive T_{regs} highly express OX40, CTLA-4 and CD25 and can be depleted to achieve stronger anti-tumor effects in combinatorial strategies [195–199]. One study investigated the effect of combining CD3xEGFR-armed T cells with T_{reg}-depleting ipilimumab (anti-CTLA-4) on T-cell activation and proliferation when co-cultured with tumor cell lines or primary tumor cells and found enhanced T-cell-mediated cytotoxicity and increased T-cell proliferation [200]. Thus far, there are some promising preclinical results for combining CD3-BsAbs with IDO blockade, MDSC depletion and T_{reg} depletion, warranting further exploitation of these combinations.

Instead of decreasing T-cell inhibitory signals, another approach would be to trigger stimulatory receptors on T cells, which could be induced by administering agonistic antibodies for these receptors on T cells, such as CD28 and 4-1BB. This approach parallels the addition of a costimulatory intracellular signaling domain to improve efficacy for second generation CAR T cells [201]. The combination of CD3-BsAbs with costimulatory antibodies has been successfully used in many different tumor models in mice [202,203]. Chiu et al. showed in a humanized mouse model that combination of a CD3xPSMA BsAb with a costimulatory agonistic 4-1BB Ab greatly enhanced anti-tumor efficacy [204]. The combination successfully improved the survival of mice bearing large tumors in contrast to CD3-BsAb monotherapy and, more importantly, generated a memory response that protected surviving mice from a second tumor challenge. However, weight loss was reported in the mice receiving the combination treatment, which is in line with reported toxicities for the administration of bivalent agonistic 4-1BB costimulatory Abs [205,206]. Conditional costimulation only in the tumor TME can be generated by CD28xTAA BsAbs [207]. Using this localized costimulation, Skokos et al. observed no toxicities in *in vitro* assays as well as in cynomolgus monkey toxicity studies, while these combinations still displayed impressive enhancements in anti-tumor activity in various mouse models [207]. Therefore, the combination of CD3-BsAbs with TME-targeted costimulatory BsAbs seems promising. Furthermore, additional costimulation has been reported to protect T cells from Fas-mediated apoptosis after activation by CD3-BsAb [208]. Currently, a clinical trial is investigating the combination of CD3xMUC1 with CD28xMUC1 and we are looking forward to seeing if the promising preclinical results will translate to clinical efficacy (NCT04590326). Finally, T-cell-sustaining cytokines can be coinjected, or engineered onto CD3-BsAbs. Rossi et al. reported that IFN- α enhanced T-cell activation and delayed tumor outgrowth in two mouse models [209]. Schmol et al. linked IL-15 to a bispecific natural killer (NK) cell engager and showed enhanced NK cell proliferation, activation and survival *in vitro*. This finding could potentially be translated to CD3-BsAbs as well, since IL-15 also promotes T-cell survival [210]. An overview of the solutions to improve T-cell quality is depicted in Figure 4.




Figure 4. Solutions for hurdle 3: impaired TIL quality. (1) Targeting immunosuppressive cells such as CAFs, T_{regs} and tumor-associated macrophages (TAMs) depletes producers of immunosuppressive cytokines, thereby decreasing suppressive signals for T cells, improving their effector functions. (2) Direct blockade of immunosuppressive cytokines, instead of targeting their cellular producers, is able to achieve the same. (3) Addition of costimulation provides positive signals for T-cell effector functions and survival. (4) Providing sustaining cytokines can also improve T-cell functioning. (5) Blockade of immune checkpoints can prevent T-cell dysfunction and allow stronger anti-tumor responses.

3. Future Perspectives

CD3-BsAbs are an emerging and promising class of immunotherapy due to their impressive treatment outcomes in hematological malignancies, however, prominent anti-tumor efficacy in solid tumors still needs to be delivered clinically. Particularly, a whole array of hurdles arises in solid cancers, ranging from on-target off-tumor toxicities and the absence of T-cell infiltration in the TME, to hampered T-cell function attributable to a hostile and immunosuppressive microenvironment. Due to continuous research efforts, more tumor-specific TAAs become available every year for use in CD3-BsAb formats. Combined with constantly evolving technologies allowing conditional masking of BsAbs, on-target off-tumor effects should be manageable in the near future. Some interesting pre-clinical concepts have been published to enhance T-cell infiltration in the tumor, such as pre-treatment with OV to facilitate massive T-cell infiltration and create an inflammatory TME. OV treatment seems most promising, as the inflamed TME also contributes to the quality of the TILs. Many options are available in terms of improving TIL quality, however, apart from checkpoint blockade or costimulation, only very few of them have been tested in combination with CD3-BsAbs. Nevertheless, based on elegant preclinical studies, we are convinced that a combination CD3-BsAbs with (tumor-targeted) costimulation is able to overcome many of the hurdles set by the TME of solid tumors.

We anticipate a future where the immune landscape of the tumor from a biopsy guides the selection of the best treatment combination. However, since many of these combinations have only just started to emerge, it will be intriguing to follow the results of new pre-clinical studies and see how those results translate to the clinic. Ultimately, based on these novel approaches, we foresee a bright future for CD3-BsAb-based therapy in solid

tumors and are interested to see if comparable anti-tumor efficacy can be observed in solid cancer as seen in hematological cancers.

Author Contributions: Original draft preparation: J.M. and T.v.H.; review and draft editing: K.K., P.E. and A.F.L.; supervision: J.S. All authors have read and agreed to the published version of the manuscript.

Funding: J.M. works on a grant provided by Genmab to T.v.H., K.K., P.E., A.F.L. and J.S. have ownership interests (including stocks, warrants, patents, etc.) in Genmab.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: The authors thank Gijs Zom, Katy Lloyd, Lars Guelen and Judith Klimovsky for critically reading the manuscript. All figures were created with BioRender software ([BioRender.com](https://www.biorender.com)).

Conflicts of Interest: K.K., P.E., A.F.L. and J.S. are all Genmab employees and own stock and/or warrants in the company. Furthermore, K.K., P.E., A.F.L. and J.S. are listed as inventors on patents relating to CD3-BsAb or the DuoBody BsAb technology platform.

References

1. van der Neut Kolfschoten, M.; Schuurman, J.; Losen, M.; Bleeker, W.K.; Martinez-Martinez, P.; Vermeulen, E.; den Bleker, T.H.; Wiegman, L.; Vink, T.; Aarden, L.A.; et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. *Science* **2007**, *317*, 1554–1557. [[CrossRef](#)] [[PubMed](#)]
2. Dahlen, E.; Veitonmaki, N.; Norlen, P. Bispecific antibodies in cancer immunotherapy. *Ther. Adv. Vaccines Immunother.* **2018**, *6*, 3–17. [[CrossRef](#)] [[PubMed](#)]
3. Xu, H.; Cheng, M.; Guo, H.; Chen, Y.; Huse, M.; Cheung, N.K. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. *Cancer Immunol. Res.* **2015**, *3*, 266–277. [[CrossRef](#)] [[PubMed](#)]
4. Wu, Z.; Cheung, N.V. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. *Pharmacol. Ther.* **2018**, *182*, 161–175. [[CrossRef](#)] [[PubMed](#)]
5. Fife, B.T.; Guleria, I.; Gubbels Bupp, M.; Eagar, T.N.; Tang, Q.; Bour-Jordan, H.; Yagita, H.; Azuma, M.; Sayegh, M.H.; Bluestone, J.A. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. *J. Exp. Med.* **2006**, *203*, 2737–2747. [[CrossRef](#)]
6. Miliotou, A.N.; Papadopoulou, L.C. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. *Curr. Pharm. Biotechnol.* **2018**, *19*, 5–18. [[CrossRef](#)]
7. Slaney, C.Y.; Wang, P.; Darcy, P.K.; Kershaw, M.H. CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment. *Cancer Discov.* **2018**, *8*, 924–934. [[CrossRef](#)]
8. Sadelain, M. CD19 CAR T Cells. *Cell* **2017**, *171*, 1471. [[CrossRef](#)]
9. Scholler, J.; Brady, T.L.; Binder-Scholl, G.; Hwang, W.T.; Plesa, G.; Hege, K.M.; Vogel, A.N.; Kalos, M.; Riley, J.L.; Deeks, S.G.; et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Sci. Transl. Med.* **2012**, *4*, 132ra153. [[CrossRef](#)]
10. Labrijn, A.F.; Janmaat, M.L.; Reichert, J.M.; Parren, P. Bispecific antibodies: A mechanistic review of the pipeline. *Nat. Rev. Drug Discov.* **2019**, *18*, 585–608. [[CrossRef](#)]
11. Suurs, F.V.; Lub-de Hooge, M.N.; de Vries, E.G.E.; de Groot, D.J.A. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. *Pharmacol. Ther.* **2019**, *201*, 103–119. [[CrossRef](#)] [[PubMed](#)]
12. Borlak, J.; Langer, F.; Spanel, R.; Schondorfer, G.; Dittrich, C. Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors. *Oncotarget* **2016**, *7*, 28059–28074. [[CrossRef](#)] [[PubMed](#)]
13. Clynes, R.A.; Desjarlais, J.R. Redirected T Cell Cytotoxicity in Cancer Therapy. *Annu. Rev. Med.* **2019**, *70*, 437–450. [[CrossRef](#)] [[PubMed](#)]
14. Przepiorka, D.; Ko, C.W.; Deisseroth, A.; Yancey, C.L.; Candau-Chacon, R.; Chiu, H.J.; Gehrke, B.J.; Gomez-Broughton, C.; Kane, R.C.; Kirshner, S.; et al. FDA Approval: Blinatumomab. *Clin. Cancer Res.* **2015**, *21*, 4035–4039. [[CrossRef](#)] [[PubMed](#)]
15. Martinelli, G.; Dombret, H.; Chevallier, P.; Ottmann, O.G.; Goekbuget, N.; Topp, M.S.; Fielding, A.K.; Sterling, L.R.; Benjamin, J.; Stein, A.S. Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). *Blood* **2015**, *126*, 679. [[CrossRef](#)]
16. Kantarjian, H.; Stein, A.; Gokbuget, N.; Fielding, A.K.; Schuh, A.C.; Ribera, J.M.; Wei, A.; Dombret, H.; Foa, R.; Bassan, R.; et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. *N. Engl. J. Med.* **2017**, *376*, 836–847. [[CrossRef](#)] [[PubMed](#)]

17. Franquiz, M.J.; Short, N.J. Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy. *Biologics* **2020**, *14*, 23–34. [[CrossRef](#)] [[PubMed](#)]
18. Lau, K.M.; Saunders, I.M.; Goodman, A.M. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. *J. Oncol. Pharm. Pract.* **2020**. [[CrossRef](#)]
19. Zhao, Y.; Aldoss, I.; Qu, C.; Crawford, J.C.; Gu, Z.; Allen, E.K.; Zamora, A.E.; Alexander, T.B.; Wang, J.; Goto, H.; et al. Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL. *Blood* **2020**. [[CrossRef](#)]
20. Uy, G.L.; Aldoss, I.; Foster, M.C.; Sayre, P.H.; Wieduwilt, M.J.; Advani, A.S.; Godwin, J.E.; Arellano, M.L.; Sweet, K.; Emadi, A.; et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. *Blood* **2020**. [[CrossRef](#)]
21. Hutchings, M.; Lugtenburg, P.; Mous, R.; Clausen, M.R.; Chamuleau, M.; Linton, K.; Rule, S.; Lopez, J.S.; Oliveri, R.S.; DeMarco, D.; et al. Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial. *J. Clin. Oncol.* **2020**, *38*, 8009. [[CrossRef](#)]
22. Bannerji, R.; Allan, J.N.; Arnason, J.E.; Brown, J.R.; Advani, R.H.; Barnes, J.A.; Ansell, S.M.; O'Brien, S.M.; Chavez, J.; Duell, J.; et al. Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). *Blood* **2019**, *134*, 762. [[CrossRef](#)]
23. Schuster, S.J.; Bartlett, N.L.; Assouline, S.; Yoon, S.-S.; Bosch, F.; Sehn, L.H.; Cheah, C.Y.; Shadman, M.; Gregory, G.P.; Ku, M.; et al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. *Blood* **2019**, *134*, 6. [[CrossRef](#)]
24. Varghese, B.; Menon, J.; Rodriguez, L.; Haber, L.; Olson, K.; Duramad, P.; Oyejide, A.; Smith, E.; Thurston, G.; Kirshner, J. A Novel CD20×CD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice. *Blood* **2014**, *124*, 4501. [[CrossRef](#)]
25. Teachey, D.T.; Rheingold, S.R.; Maude, S.L.; Zugmaier, G.; Barrett, D.M.; Seif, A.E.; Nichols, K.E.; Suppa, E.K.; Kalos, M.; Berg, R.A.; et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. *Blood* **2013**, *121*, 5154–5157. [[CrossRef](#)]
26. Shimabukuro-Vornhagen, A.; Godel, P.; Subklewe, M.; Stemmler, H.J.; Schlosser, H.A.; Schlaak, M.; Kochanek, M.; Boll, B.; von Bergwelt-Baildon, M.S. Cytokine release syndrome. *J. Immunother. Cancer* **2018**, *6*, 56. [[CrossRef](#)]
27. Maude, S.L.; Teachey, D.T.; Porter, D.L.; Grupp, S.A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood* **2015**, *125*, 4017–4023. [[CrossRef](#)]
28. Strohl, W.R.; Naso, M. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. *Antibodies* **2019**, *8*, 41. [[CrossRef](#)]
29. Li, J.; Piskol, R.; Ybarra, R.; Chen, Y.J.; Li, J.; Slaga, D.; Hristopoulos, M.; Clark, R.; Modrusan, Z.; Totpal, K.; et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. *Sci. Transl. Med.* **2019**, *11*. [[CrossRef](#)]
30. Giavridis, T.; van der Stegen, S.J.C.; Eyquem, J.; Hamieh, M.; Piersigilli, A.; Sadelain, M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat. Med.* **2018**, *24*, 731–738. [[CrossRef](#)]
31. Norelli, M.; Camisa, B.; Barbiera, G.; Falcone, L.; Purevdorj, A.; Genua, M.; Sanvito, F.; Ponzoni, M.; Doglioni, C.; Cristofori, P.; et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. *Nat. Med.* **2018**, *24*, 739–748. [[CrossRef](#)] [[PubMed](#)]
32. Iwata, Y.; Sasaki, M.; Harada, A.; Taketo, J.; Hara, T.; Akai, S.; Ishiguro, T.; Narita, A.; Kaneko, A.; Mishima, M. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy. *Toxicol. Appl. Pharmacol.* **2019**, *379*, 114657. [[CrossRef](#)] [[PubMed](#)]
33. Deppisch, N.; Ruf, P.; Eissler, N.; Neff, F.; Buhmann, R.; Lindhofer, H.; Mocikat, R. Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery. *Mol. Cancer Ther.* **2015**, *14*, 1877–1883. [[CrossRef](#)]
34. Trinklein, N.D.; Pham, D.; Schellenberger, U.; Buelow, B.; Boudreau, A.; Choudhry, P.; Clarke, S.C.; Dang, K.; Harris, K.E.; Iyer, S.; et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. *MAbs* **2019**, *11*, 639–652. [[CrossRef](#)] [[PubMed](#)]
35. Leong, S.R.; Sukumaran, S.; Hristopoulos, M.; Totpal, K.; Stainton, S.; Lu, E.; Wong, A.; Tam, L.; Newman, R.; Vuilleminot, B.R.; et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. *Blood* **2017**, *129*, 609–618. [[CrossRef](#)]
36. Staflin, K.; Zuch de Zafra, C.L.; Schutt, L.K.; Clark, V.; Zhong, F.; Hristopoulos, M.; Clark, R.; Li, J.; Mathieu, M.; Chen, X.; et al. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. *JCI Insight* **2020**, *5*. [[CrossRef](#)]
37. Vafa, O.; Trinklein, N.D. Perspective: Designing T-Cell Engagers With Better Therapeutic Windows. *Front. Oncol.* **2020**, *10*, 446. [[CrossRef](#)]
38. Heiss, M.M.; Murawa, P.; Koralewski, P.; Kutarska, E.; Kolesnik, O.O.; Ivanchenko, V.V.; Dudnichenko, A.S.; Aleknaviciene, B.; Razbadauskas, A.; Gore, M.; et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. *Int. J. Cancer* **2010**, *127*, 2209–2221. [[CrossRef](#)]

39. Riesenber, R.; Buchner, A.; Pohla, H.; Lindhofer, H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). *J. Histochem. Cytochem.* **2001**, *49*, 911–917. [[CrossRef](#)]
40. Wang, L.; Hoseini, S.S.; Xu, H.; Ponomarev, V.; Cheung, N.K. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. *Cancer Immunol. Res.* **2019**, *7*, 2013–2024. [[CrossRef](#)]
41. Labrijn, A.F.; Meesters, J.I.; Bunce, M.; Armstrong, A.A.; Somani, S.; Nesspor, T.C.; Chiu, M.L.; Altintas, I.; Verploegen, S.; Schuurman, J.; et al. Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models. *Sci. Rep.* **2017**, *7*, 2476. [[CrossRef](#)]
42. Oates, J.; Hassan, N.J.; Jakobsen, B.K. ImmTACs for targeted cancer therapy: Why, what, how, and which. *Mol. Immunol.* **2015**, *67*, 67–74. [[CrossRef](#)] [[PubMed](#)]
43. Chen, C.; Wang, Y.; Zhong, K.; Jiang, C.; Wang, L.; Yuan, Z.; Nie, C.; Xu, J.; Guo, G.; Zhou, L.; et al. Frequent B7-H3 overexpression in craniopharyngioma. *Biochem. Biophys. Res. Commun.* **2019**, *514*, 379–385. [[CrossRef](#)]
44. Crawford, A.; Haber, L.; Kelly, M.P.; Vazzana, K.; Canova, L.; Ram, P.; Pawashe, A.; Finney, J.; Jalal, S.; Chiu, D.; et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. *Sci. Transl. Med.* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
45. Fisher, T.S.; Hooper, A.T.; Lucas, J.; Clark, T.H.; Rohner, A.K.; Peano, B.; Elliott, M.W.; Tsaparikos, K.; Wang, H.; Golas, J.; et al. A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice. *Cancer Immunol. Immunother.* **2018**, *67*, 247–259. [[CrossRef](#)] [[PubMed](#)]
46. Fu, M.; He, Q.; Guo, Z.; Zhou, X.; Li, H.; Zhao, L.; Tang, H.; Zhou, X.; Zhu, H.; Shen, G.; et al. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor. *Front. Immunol.* **2019**, *10*, 1396. [[CrossRef](#)] [[PubMed](#)]
47. Fu, M.P.; Guo, Z.L.; Tang, H.L.; Zhu, H.F.; Shen, G.X.; He, Y.; Lei, P. Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats. *Curr. Med. Sci.* **2020**, *40*, 28–34. [[CrossRef](#)]
48. Hettich, M.; Lahoti, J.; Prasad, S.; Niedermann, G. Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing gamma-Irradiation. *Cancer Res.* **2016**, *76*, 4673–4683. [[CrossRef](#)]
49. Huang, L.; Xie, K.; Li, H.; Wang, R.; Xu, X.; Chen, K.; Gu, H.; Fang, J. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody. *Drug Des. Dev. Ther.* **2020**, *14*, 3201–3214. [[CrossRef](#)]
50. Iizuka, A.; Nonomura, C.; Ashizawa, T.; Kondou, R.; Ohshima, K.; Sugino, T.; Mitsuya, K.; Hayashi, N.; Nakasu, Y.; Maruyama, K.; et al. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer. *Clin. Cancer Res.* **2019**, *25*, 2925–2934. [[CrossRef](#)]
51. Kamada, H.; Taki, S.; Nagano, K.; Inoue, M.; Ando, D.; Mukai, Y.; Higashisaka, K.; Yoshioka, Y.; Tsutsumi, Y.; Tsunoda, S. Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3. *Biochem. Biophys. Res. Commun.* **2015**, *456*, 908–912. [[CrossRef](#)] [[PubMed](#)]
52. Kurosawa, N.; Wakata, Y.; Ida, K.; Midorikawa, A.; Isobe, M. High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager. *Sci. Rep.* **2019**, *9*, 9827. [[CrossRef](#)] [[PubMed](#)]
53. Li, H.; Huang, C.; Zhang, Z.; Feng, Y.; Wang, Z.; Tang, X.; Zhong, K.; Hu, Y.; Guo, G.; Zhou, L.; et al. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody. *Front. Oncol.* **2020**, *10*, 1527. [[CrossRef](#)] [[PubMed](#)]
54. Ma, J.; Shang, T.; Ma, P.; Sun, X.; Zhao, J.; Sun, X.; Zhang, M. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo. *Investig. New Drugs* **2019**, *37*, 1036–1043. [[CrossRef](#)] [[PubMed](#)]
55. Ma, W.; Ma, J.; Lei, T.; Zhao, M.; Zhang, M. Targeting immunotherapy for bladder cancer by using anti-CD3x CD155 bispecific antibody. *J. Cancer* **2019**, *10*, 5153–5161. [[CrossRef](#)] [[PubMed](#)]
56. Ma, W.; Ma, J.; Ma, P.; Lei, T.; Zhao, M.; Zhang, M. Targeting immunotherapy for bladder cancer using anti-CD3x B7-H3 bispecific antibody. *Cancer Med.* **2018**, *7*, 5167–5177. [[CrossRef](#)]
57. Martini, S.; Figini, M.; Croce, A.; Frigerio, B.; Pennati, M.; Gianni, A.M.; De Marco, C.; Daidone, M.G.; Argueta, C.; Landesman, Y.; et al. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. *Cells* **2020**, *9*, 2231. [[CrossRef](#)]
58. Mathur, D.; Root, A.R.; Bugaj-Gaweda, B.; Bisulco, S.; Tan, X.; Fang, W.; Kearney, J.C.; Lucas, J.; Guffroy, M.; Golas, J.; et al. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers. *Clin. Cancer Res.* **2020**, *26*, 2188–2202. [[CrossRef](#)]
59. Qi, J.; Hymel, D.; Nelson, C.G.; Burke, T.R., Jr.; Rader, C. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. *Front. Immunol.* **2019**, *10*, 1994. [[CrossRef](#)]
60. Qi, J.; Li, X.; Peng, H.; Cook, E.M.; Dadashian, E.L.; Wiestner, A.; Park, H.; Rader, C. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E5467–E5476. [[CrossRef](#)]
61. Root, A.R.; Cao, W.; Li, B.; LaPan, P.; Meade, C.; Sanford, J.; Jin, M.; O’Sullivan, C.; Cummins, E.; Lambert, M.; et al. Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer. *Antibodies* **2016**, *5*, 6. [[CrossRef](#)]
62. Ruan, S.; Lin, M.; Zhu, Y.; Lum, L.; Thakur, A.; Jin, R.; Shao, W.; Zhang, Y.; Hu, Y.; Huang, S.; et al. Integrin beta4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis. *Cancer Res.* **2020**, *80*, 771–783. [[CrossRef](#)]
63. Satta, A.; Grazia, G.; Caroli, F.; Frigerio, B.; Di Nicola, M.; Raspagliesi, F.; Mezzanzanica, D.; Zaffaroni, N.; Gianni, A.M.; Anichini, A.; et al. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. *Front. Immunol.* **2019**, *10*, 2514. [[CrossRef](#)]

64. Satta, A.; Mezzanzanica, D.; Caroli, F.; Frigerio, B.; Di Nicola, M.; Kontermann, R.E.; Iacovelli, F.; Desideri, A.; Anichini, A.; Canevari, S.; et al. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. *MAbs* **2018**, *10*, 1084–1097. [[CrossRef](#)] [[PubMed](#)]
65. Stadler, C.R.; Bahr-Mahmud, H.; Plum, L.M.; Schmoldt, K.; Kolsch, A.C.; Tureci, O.; Sahin, U. Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. *Oncoimmunology* **2016**, *5*, e1091555. [[CrossRef](#)] [[PubMed](#)]
66. Taki, S.; Kamada, H.; Inoue, M.; Nagano, K.; Mukai, Y.; Higashisaka, K.; Yoshioka, Y.; Tsutsumi, Y.; Tsunoda, S. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. *PLoS ONE* **2015**, *10*, e0144712. [[CrossRef](#)] [[PubMed](#)]
67. Zhao, H.; Ma, J.; Lei, T.; Ma, W.; Zhang, M. The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer. *Investig. New Drugs* **2019**, *37*, 810–817. [[CrossRef](#)]
68. Zhao, L.; Yang, Y.; Zhou, P.; Ma, H.; Zhao, X.; He, X.; Wang, T.; Zhang, J.; Liu, Y.; Zhang, T. Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo with an Asymmetric Bispecific Antibody. *J. Immunother.* **2015**, *38*, 217–228. [[CrossRef](#)]
69. Zhou, Y.; Zong, H.; Han, L.; Xie, Y.; Jiang, H.; Gilly, J.; Zhang, B.; Lu, H.; Chen, J.; Sun, R.; et al. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. *J. Exp. Clin. Cancer Res.* **2020**, *39*, 87. [[CrossRef](#)]
70. Kebenko, M.; Goebeler, M.E.; Wolf, M.; Hasenburger, A.; Seggewiss-Bernhardt, R.; Ritter, B.; Rautenberg, B.; Atanackovic, D.; Kratzer, A.; Rottman, J.B.; et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors. *Oncoimmunology* **2018**, *7*, e1450710. [[CrossRef](#)]
71. Pishvaian, M.; Morse, M.A.; McDevitt, J.; Norton, J.D.; Ren, S.; Robbie, G.J.; Ryan, P.C.; Soukharev, S.; Bao, H.; Denlinger, C.S. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. *Clin. Colorectal. Cancer* **2016**, *15*, 345–351. [[CrossRef](#)] [[PubMed](#)]
72. Taberero, J.; Melero, I.; Ros, W.; Argiles, G.; Marabelle, A.; Rodriguez-Ruiz, M.E.; Albanell, J.; Calvo, E.; Moreno, V.; Cleary, J.M.; et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). *J. Clin. Oncol.* **2017**, *35*, 3002. [[CrossRef](#)]
73. Middleton, M.R.; McAlpine, C.; Woodcock, V.K.; Corrie, P.; Infante, J.R.; Steven, N.M.; Evans, T.R.J.; Anthoney, A.; Shoushtari, A.N.; Hamid, O.; et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. *Clin. Cancer Res.* **2020**. [[CrossRef](#)] [[PubMed](#)]
74. Hummel, H.-D.; Kufer, P.; Grüllich, C.; Deschler-Baier, B.; Chatterjee, M.; Goebeler, M.-E.; Miller, K.; Santis, M.D.; Loidl, W.C.; Buck, A.; et al. Phase 1 study of pasotuzumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). *J. Clin. Oncol.* **2019**, *37*, 5034. [[CrossRef](#)]
75. Lutterbuese, R.; Raum, T.; Kischel, R.; Hoffmann, P.; Mangold, S.; Rattel, B.; Friedrich, M.; Thomas, O.; Lorenzowski, G.; Rau, D.; et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 12605–12610. [[CrossRef](#)] [[PubMed](#)]
76. Ellerman, D. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. *Methods* **2019**, *154*, 102–117. [[CrossRef](#)]
77. Chen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. *Nature* **2017**, *541*, 321–330. [[CrossRef](#)]
78. Lanitis, E.; Dangaj, D.; Irving, M.; Coukos, G. Mechanisms regulating T-cell infiltration and activity in solid tumors. *Ann. Oncol.* **2017**, *28*, xii18–xii32. [[CrossRef](#)]
79. Groeneveldt, C.; van Hall, T.; van der Burg, S.H.; Ten Dijke, P.; van Montfoort, N. Immunotherapeutic Potential of TGF-beta Inhibition and Oncolytic Viruses. *Trends Immunol.* **2020**, *41*, 406–420. [[CrossRef](#)]
80. Kuczek, D.E.; Larsen, A.M.H.; Thorseth, M.L.; Carretta, M.; Kalvisa, A.; Siersbaek, M.S.; Simoes, A.M.C.; Roslind, A.; Engelholm, L.H.; Noessner, E.; et al. Collagen density regulates the activity of tumor-infiltrating T cells. *J. Immunother. Cancer* **2019**, *7*, 68. [[CrossRef](#)]
81. Strohle, M.A.; Lefering, R.; Bulian, D.R.; Heiss, M.M. Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy. *Med. Hypotheses* **2014**, *82*, 295–299. [[CrossRef](#)] [[PubMed](#)]
82. Kumar, B.V.; Connors, T.J.; Farber, D.L. Human T Cell Development, Localization, and Function throughout Life. *Immunity* **2018**, *48*, 202–213. [[CrossRef](#)] [[PubMed](#)]
83. Halin, C.; Scimone, M.L.; Bonasio, R.; Gauguier, J.M.; Mempel, T.R.; Quackenbush, E.; Proia, R.L.; Mandala, S.; von Andrian, U.H. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. *Blood* **2005**, *106*, 1314–1322. [[CrossRef](#)] [[PubMed](#)]
84. Yan, Y.; Chen, R.; Wang, X.; Hu, K.; Huang, L.; Lu, M.; Hu, Q. CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. *Front. Cell Dev. Biol.* **2019**, *7*, 212. [[CrossRef](#)] [[PubMed](#)]
85. Groom, J.R.; Luster, A.D. CXCR3 in T cell function. *Exp. Cell Res.* **2011**, *317*, 620–631. [[CrossRef](#)]
86. Chow, M.T.; Luster, A.D. Chemokines in cancer. *Cancer Immunol. Res.* **2014**, *2*, 1125–1131. [[CrossRef](#)]
87. Iijima, N.; Iwasaki, A. Tissue instruction for migration and retention of TRM cells. *Trends Immunol.* **2015**, *36*, 556–564. [[CrossRef](#)]
88. Amsen, D.; van Gisbergen, K.; Hombrink, P.; van Lier, R.A.W. Tissue-resident memory T cells at the center of immunity to solid tumors. *Nat. Immunol.* **2018**, *19*, 538–546. [[CrossRef](#)] [[PubMed](#)]

89. Thommen, D.S.; Schumacher, T.N. T Cell Dysfunction in Cancer. *Cancer Cell* **2018**, *33*, 547–562. [[CrossRef](#)]
90. Tormoen, G.W.; Crittenden, M.R.; Gough, M.J. Role of the immunosuppressive microenvironment in immunotherapy. *Adv. Radiat. Oncol.* **2018**, *3*, 520–526. [[CrossRef](#)]
91. Grywalska, E.; Pasiarski, M.; Gozdz, S.; Rolinski, J. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. *Onco Targets Ther.* **2018**, *11*, 6505–6524. [[CrossRef](#)] [[PubMed](#)]
92. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674. [[CrossRef](#)] [[PubMed](#)]
93. Wee, P.; Wang, Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers* **2017**, *9*, 52. [[CrossRef](#)]
94. Vigneron, N. Human Tumor Antigens and Cancer Immunotherapy. *Biomed. Res. Int.* **2015**, *2015*, 948501. [[CrossRef](#)] [[PubMed](#)]
95. Bansal, A.; Singh, M.P.; Rai, B. Human papillomavirus-associated cancers: A growing global problem. *Int. J. Appl. Basic Med. Res.* **2016**, *6*, 84–89. [[CrossRef](#)] [[PubMed](#)]
96. Wu, J.; Zhao, W.; Zhou, B.; Su, Z.; Gu, X.; Zhou, Z.; Chen, S. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis. *Genomics Proteomics Bioinform.* **2018**, *16*, 276–282. [[CrossRef](#)] [[PubMed](#)]
97. Koster, J.; Plasterk, R.H.A. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. *Sci. Rep.* **2019**, *9*, 6577. [[CrossRef](#)]
98. Kraus, M.H.; Popescu, N.C.; Amsbaugh, S.C.; King, C.R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. *EMBO J.* **1987**, *6*, 605–610. [[CrossRef](#)]
99. Imrich, S.; Hachmeister, M.; Gires, O. EpCAM and its potential role in tumor-initiating cells. *Cell Adh. Migr.* **2012**, *6*, 30–38. [[CrossRef](#)]
100. Trenevskaja, I.; Li, D.; Banham, A.H. Therapeutic Antibodies against Intracellular Tumor Antigens. *Front. Immunol.* **2017**, *8*, 1001. [[CrossRef](#)]
101. Bunk, S.; Hofmann, M.; Unverdorben, F.; Hutt, M.; Pszolla, G.; Schwöbel, F.; Wagner, C.; Yousef, S.; Schuster, H.; Missel, S.; et al. Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER[®]) Molecules. *Blood* **2019**, *134*, 3368. [[CrossRef](#)]
102. Maruta, M.; Ochi, T.; Tanimoto, K.; Asai, H.; Saitou, T.; Fujiwara, H.; Imamura, T.; Takenaka, K.; Yasukawa, M. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirectioned T cells for the development of antibody-based T-cell therapy. *Sci. Rep.* **2019**, *9*, 13293. [[CrossRef](#)] [[PubMed](#)]
103. Dao, T.; Pankov, D.; Scott, A.; Korontsvit, T.; Zakhaleva, V.; Xu, Y.; Xiang, J.; Yan, S.; de Moraes Guerreiro, M.D.; Veomett, N.; et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. *Nat. Biotechnol.* **2015**, *33*, 1079–1086. [[CrossRef](#)] [[PubMed](#)]
104. Marijt, K.A.; Doorduijn, E.M.; van Hall, T. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I(low) cancers. *Mol. Immunol.* **2019**, *113*, 43–49. [[CrossRef](#)] [[PubMed](#)]
105. Prior, I.A.; Lewis, P.D.; Mattos, C. A comprehensive survey of Ras mutations in cancer. *Cancer Res.* **2012**, *72*, 2457–2467. [[CrossRef](#)] [[PubMed](#)]
106. Rensing, M.E.; de Jong, J.H.; Brandt, R.M.; Drijfhout, J.W.; Benckhuijsen, W.E.; Schreuder, G.M.; Offringa, R.; Kast, W.M.; Melief, C.J. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. *Eur. J. Immunol.* **1999**, *29*, 1292–1303. [[CrossRef](#)]
107. Bacac, M.; Klein, C.; Umana, P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. *Oncoimmunology* **2016**, *5*, e1203498. [[CrossRef](#)]
108. Slaga, D.; Ellerman, D.; Lombana, T.N.; Vij, R.; Li, J.; Hristopoulos, M.; Clark, R.; Johnston, J.; Shelton, A.; Mai, E.; et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. *Sci. Transl. Med.* **2018**, *10*. [[CrossRef](#)]
109. Bacac, M.; Fauti, T.; Sam, J.; Colombetti, S.; Weinzierl, T.; Ouaret, D.; Bodmer, W.; Lehmann, S.; Hofer, T.; Hosse, R.J.; et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. *Clin. Cancer Res.* **2016**, *22*, 3286–3297. [[CrossRef](#)]
110. Panowski, S.H.; Kuo, T.C.; Zhang, Y.; Chen, A.; Geng, T.; Aschenbrenner, L.; Kamperschroer, C.; Pascua, E.; Chen, W.; Delaria, K.; et al. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma. *Mol. Cancer Ther.* **2019**, *18*, 2008–2020. [[CrossRef](#)]
111. Mazor, Y.; Sachsenmeier, K.F.; Yang, C.; Hansen, A.; Filderman, J.; Mulgrew, K.; Wu, H.; Dall’Acqua, W.F. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. *Sci. Rep.* **2017**, *7*, 40098. [[CrossRef](#)] [[PubMed](#)]
112. DeClerck, Y.A.; Mercurio, A.M.; Stack, M.S.; Chapman, H.A.; Zutter, M.M.; Muschel, R.J.; Raz, A.; Matrisian, L.M.; Sloane, B.F.; Noel, A.; et al. Proteases, extracellular matrix, and cancer: A workshop of the path B study section. *Am. J. Pathol.* **2004**, *164*, 1131–1139. [[CrossRef](#)]
113. Stubbs, M.; McSheehy, P.M.; Griffiths, J.R.; Bashford, C.L. Causes and consequences of tumour acidity and implications for treatment. *Mol. Med. Today* **2000**, *6*, 15–19. [[CrossRef](#)]
114. Boustany, L.M.; Wong, L.; White, C.W.; Diep, L.; Huang, Y.; Liu, S.; Richardson, J.H.; Kavanaugh, W.M.; Irving, B.A. Abstract A164: EGFR-CD3 bispecific Probody[™] therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies. *Mol. Cancer Ther.* **2018**, *17*, A164. [[CrossRef](#)]

115. Panchal, A.; Seto, P.; Wall, R.; Hillier, B.J.; Zhu, Y.; Krakow, J.; Datt, A.; Pongo, E.; Bagheri, A.; Chen, T.T.; et al. COBRA: A highly potent conditionally active T cell engager engineered for the treatment of solid tumors. *MAbs* **2020**, *12*, 1792130. [[CrossRef](#)]
116. Geiger, M.; Stubenrauch, K.-G.; Sam, J.; Richter, W.F.; Jordan, G.; Eckmann, J.; Hage, C.; Nicolini, V.; Freimoser-Grundschober, A.; Ritter, M.; et al. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. *Nat. Commun.* **2020**, *11*. [[CrossRef](#)]
117. Banaszek, A.; Bumm, T.G.P.; Nowotny, B.; Geis, M.; Jacob, K.; Wolff, M.; Trebing, J.; Kucka, K.; Kouhestani, D.; Gogishvili, T.; et al. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. *Nat. Commun.* **2019**, *10*, 5387. [[CrossRef](#)]
118. Minogue, E.; Millar, D.; Chuan, Y.; Zhang, S.; Grauwet, K.; Guo, M.; Langenbucher, A.; Benes, C.H.; Heather, J.; Minshull, J.; et al. Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC). *Blood* **2019**, *134*, 2653. [[CrossRef](#)]
119. Mandikian, D.; Takahashi, N.; Lo, A.A.; Li, J.; Eastham-Anderson, J.; Slaga, D.; Ho, J.; Hristopoulos, M.; Clark, R.; Totpal, K.; et al. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model. *Mol. Cancer Ther.* **2018**, *17*, 776–785. [[CrossRef](#)]
120. Kroesen, B.J.; ter Haar, A.; Spakman, H.; Willemse, P.; Sleijfer, D.T.; de Vries, E.G.; Mulder, N.H.; Berendsen, H.H.; Limburg, P.C.; The, T.H.; et al. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. *Cancer Immunol. Immunother.* **1993**, *37*, 400–407. [[CrossRef](#)]
121. Blanco, B.; Ramirez-Fernandez, A.; Alvarez-Vallina, L. Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies. *Front. Immunol.* **2020**, *11*, 1792. [[CrossRef](#)] [[PubMed](#)]
122. Iwahori, K.; Kakarla, S.; Velasquez, M.P.; Yu, F.; Yi, Z.; Gerken, C.; Song, X.T.; Gottschalk, S. Engager T cells: A new class of antigen-specific T cells that redirect bystander T cells. *Mol. Ther.* **2015**, *23*, 171–178. [[CrossRef](#)] [[PubMed](#)]
123. Blanco, B.; Holliger, P.; Vile, R.G.; Alvarez-Vallina, L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. *J. Immunol.* **2003**, *171*, 1070–1077. [[CrossRef](#)]
124. Compte, M.; Blanco, B.; Serrano, F.; Cuesta, A.M.; Sanz, L.; Bernad, A.; Holliger, P.; Alvarez-Vallina, L. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. *Cancer Gene Ther.* **2007**, *14*, 380–388. [[CrossRef](#)] [[PubMed](#)]
125. Everts, B.; van der Poel, H.G. Replication-selective oncolytic viruses in the treatment of cancer. *Cancer Gene Ther.* **2005**, *12*, 141–161. [[CrossRef](#)]
126. Fajardo, C.A.; Guedan, S.; Rojas, L.A.; Moreno, R.; Arias-Badia, M.; de Sostoa, J.; June, C.H.; Alemany, R. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. *Cancer Res.* **2017**, *77*, 2052–2063. [[CrossRef](#)]
127. Speck, T.; Heidbuechel, J.P.W.; Veinalde, R.; Jaeger, D.; von Kalle, C.; Ball, C.R.; Ungerechts, G.; Engeland, C.E. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors. *Clin. Cancer Res.* **2018**, *24*, 2128–2137. [[CrossRef](#)]
128. Freedman, J.D.; Hagel, J.; Scott, E.M.; Psallidas, I.; Gupta, A.; Spiers, L.; Miller, P.; Kanellakis, N.; Ashfield, R.; Fisher, K.D.; et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. *EMBO Mol. Med.* **2017**, *9*, 1067–1087. [[CrossRef](#)]
129. Porter, C.E.; Rosewell Shaw, A.; Jung, Y.; Yip, T.; Castro, P.D.; Sandulache, V.C.; Sikora, A.; Gottschalk, S.; Ittman, M.M.; Brenner, M.K.; et al. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. *Mol. Ther.* **2020**, *28*, 1251–1262. [[CrossRef](#)]
130. Yu, F.; Wang, X.; Guo, Z.S.; Bartlett, D.L.; Gottschalk, S.M.; Song, X.T. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. *Mol. Ther.* **2014**, *22*, 102–111. [[CrossRef](#)]
131. Gujar, S.; Pol, J.G.; Kroemer, G. Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies. *Oncoimmunology* **2018**, *7*, e1442169. [[CrossRef](#)] [[PubMed](#)]
132. Marchini, A.; Daeffler, L.; Pozdeev, V.I.; Angelova, A.; Rommelaere, J. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. *Front. Immunol.* **2019**, *10*, 1848. [[CrossRef](#)]
133. Russell, L.; Peng, K.W.; Russell, S.J.; Diaz, R.M. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. *BioDrugs* **2019**, *33*, 485–501. [[CrossRef](#)] [[PubMed](#)]
134. Groeneveldt, C.; Kinderman, P.; van den Wollenberg, D.J.M.; van den Oever, R.L.; Middelburg, J.; Mustafa, D.A.M.; Hoeben, R.C.; van der Burg, S.H.; van Hall, T.; van Montfoort, N. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. *J. Immunother. Cancer* **2020**, *8*. [[CrossRef](#)]
135. Henke, E.; Nandigama, R.; Ergun, S. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. *Front. Mol. Biosci.* **2019**, *6*, 160. [[CrossRef](#)] [[PubMed](#)]
136. Coulouarn, C.; Clement, B. Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma. *J. Hepatol.* **2014**, *60*, 1306–1309. [[CrossRef](#)] [[PubMed](#)]
137. Wang, X.; Luo, J.; He, L.; Cheng, X.; Yan, G.; Wang, J.; Tang, R. Hybrid pH-sensitive nanogels surface-functionalized with collagenase for enhanced tumor penetration. *J. Colloid Interface Sci.* **2018**, *525*, 269–281. [[CrossRef](#)]
138. Yoshida, E.; Kudo, D.; Nagase, H.; Suto, A.; Shimoda, H.; Suto, S.; Kakizaki, I.; Endo, M.; Hakamada, K. 4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil. *Anticancer Res.* **2018**, *38*, 5799–5804. [[CrossRef](#)]

139. Eikenes, L.; Tari, M.; Tufto, I.; Bruland, O.S.; de Lange Davies, C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. *Br. J. Cancer* **2005**, *93*, 81–88. [[CrossRef](#)]
140. Guan, X.; Chen, J.; Hu, Y.; Lin, L.; Sun, P.; Tian, H.; Chen, X. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase. *Biomaterials* **2018**, *171*, 198–206. [[CrossRef](#)]
141. Wen, Y.; Wang, C.T.; Ma, T.T.; Li, Z.Y.; Zhou, L.N.; Mu, B.; Leng, F.; Shi, H.S.; Li, Y.O.; Wei, Y.Q. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. *Cancer Sci.* **2010**, *101*, 2325–2332. [[CrossRef](#)] [[PubMed](#)]
142. Kraman, M.; Bambrough, P.J.; Arnold, J.N.; Roberts, E.W.; Magiera, L.; Jones, J.O.; Gopinathan, A.; Tuveson, D.A.; Fearon, D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein- α . *Science* **2010**, *330*, 827–830. [[CrossRef](#)] [[PubMed](#)]
143. Ohshio, Y.; Teramoto, K.; Hanaoka, J.; Tezuka, N.; Itoh, Y.; Asai, T.; Daigo, Y.; Ogasawara, K. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. *Cancer Sci.* **2015**, *106*, 134–142. [[CrossRef](#)] [[PubMed](#)]
144. Freedman, J.D.; Duffy, M.R.; Lei-Rossmann, J.; Muntzer, A.; Scott, E.M.; Hagel, J.; Campo, L.; Bryant, R.J.; Verrill, C.; Lambert, A.; et al. An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. *Cancer Res.* **2018**, *78*, 6852–6865. [[CrossRef](#)] [[PubMed](#)]
145. de Sostoa, J.; Fajardo, C.A.; Moreno, R.; Ramos, M.D.; Farrera-Sal, M.; Alemany, R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. *J. Immunother. Cancer* **2019**, *7*, 19. [[CrossRef](#)] [[PubMed](#)]
146. Yu, F.; Hong, B.; Song, X.-T. A T-cell engager-armed oncolytic vaccinia virus to target the tumor stroma. *Cancer Transl. Med.* **2017**, *3*, 122–132. [[CrossRef](#)]
147. Harryvan, T.J.; Verdegaal, E.M.E.; Hardwick, J.C.H.; Hawinkels, L.; van der Burg, S.H. Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies. *J. Clin. Med.* **2019**, *8*, 1989. [[CrossRef](#)]
148. Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.; Deonaraine, A.; Chan, D.S.; Connell, C.M.; Roberts, E.W.; Zhao, Q.; Caballero, O.L.; et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 20212–20217. [[CrossRef](#)]
149. Zboralski, D.; Hoehlig, K.; Eulberg, D.; Fromming, A.; Vater, A. Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade. *Cancer Immunol. Res.* **2017**, *5*, 950–956. [[CrossRef](#)]
150. Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E., III; Koeppen, H.; Astarita, J.L.; Cubas, R.; et al. TGF β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* **2018**, *554*, 544–548. [[CrossRef](#)]
151. Tauriello, D.V.F.; Palomo-Ponce, S.; Stork, D.; Berenguer-Llargo, A.; Badia-Ramentol, J.; Iglesias, M.; Sevillano, M.; Ibiza, S.; Canellas, A.; Hernando-Mombona, X.; et al. TGF β drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* **2018**, *554*, 538–543. [[CrossRef](#)] [[PubMed](#)]
152. Holmgaard, R.B.; Schaer, D.A.; Li, Y.; Castaneda, S.P.; Murphy, M.Y.; Xu, X.; Inigo, I.; Dobkin, J.; Manro, J.R.; Iversen, P.W.; et al. Targeting the TGF β pathway with galunisertib, a TGF β RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. *J. Immunother. Cancer* **2018**, *6*, 47. [[CrossRef](#)] [[PubMed](#)]
153. Molon, B.; Ugel, S.; Del Pozzo, F.; Soldani, C.; Zilio, S.; Avella, D.; De Palma, A.; Mauri, P.; Monegal, A.; Rescigno, M.; et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J. Exp. Med.* **2011**, *208*, 1949–1962. [[CrossRef](#)] [[PubMed](#)]
154. Rotte, A.; Jin, J.Y.; Lemaire, V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. *Ann. Oncol.* **2018**, *29*, 71–83. [[CrossRef](#)] [[PubMed](#)]
155. Borst, L.; van der Burg, S.H.; van Hall, T. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. *Clin. Cancer Res.* **2020**, *26*, 5549–5556. [[CrossRef](#)]
156. Jiang, X.; Wang, J.; Deng, X.; Xiong, F.; Ge, J.; Xiang, B.; Wu, X.; Ma, J.; Zhou, M.; Li, X.; et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. *Mol. Cancer* **2019**, *18*, 10. [[CrossRef](#)]
157. Chen, S.; Crabill, G.A.; Pritchard, T.S.; McMiller, T.L.; Wei, P.; Pardoll, D.M.; Pan, F.; Topalian, S.L. Mechanisms regulating PD-L1 expression on tumor and immune cells. *J. Immunother. Cancer* **2019**, *7*, 305. [[CrossRef](#)]
158. Chikuma, S.; Terawaki, S.; Hayashi, T.; Nabeshima, R.; Yoshida, T.; Shibayama, S.; Okazaki, T.; Honjo, T. PD-1-mediated suppression of IL-2 production induces CD8 $^{+}$ T cell anergy in vivo. *J. Immunol.* **2009**, *182*, 6682–6689. [[CrossRef](#)]
159. Kobold, S.; Pantelyushin, S.; Rataj, F.; Vom Berg, J. Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. *Front. Oncol.* **2018**, *8*, 285. [[CrossRef](#)]
160. Schreiner, J.; Thommen, D.S.; Herzig, P.; Bacac, M.; Klein, C.; Roller, A.; Belousov, A.; Levitsky, V.; Savic, S.; Moersig, W.; et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. *Oncoimmunology* **2016**, *5*, e1062969. [[CrossRef](#)]
161. Huang, S.; Apasov, S.; Koshiba, M.; Sitkovsky, M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. *Blood* **1997**, *90*, 1600–1610. [[CrossRef](#)] [[PubMed](#)]

162. Linden, J.; Cekic, C. Regulation of lymphocyte function by adenosine. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 2097–2103. [[CrossRef](#)] [[PubMed](#)]
163. Osada, T.; Patel, S.P.; Hammond, S.A.; Osada, K.; Morse, M.A.; Lyster, H.K. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. *Cancer Immunol. Immunother.* **2015**, *64*, 677–688. [[CrossRef](#)] [[PubMed](#)]
164. Singer, K.; Gottfried, E.; Kreutz, M.; Mackensen, A. Suppression of T-cell responses by tumor metabolites. *Cancer Immunol. Immunother.* **2011**, *60*, 425–431. [[CrossRef](#)] [[PubMed](#)]
165. Young, A.; Mittal, D.; Stagg, J.; Smyth, M.J. Targeting cancer-derived adenosine: New therapeutic approaches. *Cancer Discov.* **2014**, *4*, 879–888. [[CrossRef](#)]
166. Yin, Z.; Bai, L.; Li, W.; Zeng, T.; Tian, H.; Cui, J. Targeting T cell metabolism in the tumor microenvironment: An anti-cancer therapeutic strategy. *J. Exp. Clin. Cancer Res.* **2019**, *38*, 403. [[CrossRef](#)]
167. Zhao, E.; Maj, T.; Kryczek, I.; Li, W.; Wu, K.; Zhao, L.; Wei, S.; Crespo, J.; Wan, S.; Vatan, L.; et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. *Nat. Immunol.* **2016**, *17*, 95–103. [[CrossRef](#)]
168. Lee, G.K.; Park, H.J.; Macleod, M.; Chandler, P.; Munn, D.H.; Mellor, A.L. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. *Immunology* **2002**, *107*, 452–460. [[CrossRef](#)]
169. Chen, W.; Jin, W.; Hardegen, N.; Lei, K.J.; Li, L.; Marinos, N.; McGrady, G.; Wahl, S.M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J. Exp. Med.* **2003**, *198*, 1875–1886. [[CrossRef](#)]
170. Gorelik, L.; Constant, S.; Flavell, R.A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. *J. Exp. Med.* **2002**, *195*, 1499–1505. [[CrossRef](#)]
171. Yoon, J.H.; Jung, S.M.; Park, S.H.; Kato, M.; Yamashita, T.; Lee, I.K.; Sudo, K.; Nakae, S.; Han, J.S.; Kim, O.H.; et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. *EMBO Mol. Med.* **2013**, *5*, 1720–1739. [[CrossRef](#)] [[PubMed](#)]
172. Mittal, S.K.; Cho, K.J.; Ishido, S.; Roche, P.A. Interleukin 10 (IL-10)-mediated Immunosuppression: March-i induction regulates antigen presentation by macrophages but not Dendritic cells. *J. Biol. Chem.* **2015**, *290*, 27158–27167. [[CrossRef](#)] [[PubMed](#)]
173. Steinbrink, K.; Graulich, E.; Kubsch, S.; Knop, J.; Enk, A.H. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. *Blood* **2002**, *99*, 2468–2476. [[CrossRef](#)] [[PubMed](#)]
174. Rodriguez, P.C.; Zea, A.H.; DeSalvo, J.; Culotta, K.S.; Zabaleta, J.; Quiceno, D.G.; Ochoa, J.B.; Ochoa, A.C. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. *J. Immunol.* **2003**, *171*, 1232–1239. [[CrossRef](#)] [[PubMed](#)]
175. Taheri, F.; Ochoa, J.B.; Faghiri, Z.; Culotta, K.; Park, H.J.; Lan, M.S.; Zea, A.H.; Ochoa, A.C. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. *Clin. Cancer Res.* **2001**, *7*, 958s–965s. [[PubMed](#)]
176. Steggerda, S.M.; Bennett, M.K.; Chen, J.; Emberley, E.; Huang, T.; Janes, J.R.; Li, W.; MacKinnon, A.L.; Makkouk, A.; Marguier, G.; et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. *J. Immunother. Cancer* **2017**, *5*, 101. [[CrossRef](#)] [[PubMed](#)]
177. Ni, G.; Wang, T.; Walton, S.; Zhu, B.; Chen, S.; Wu, X.; Wang, Y.; Wei, M.Q.; Liu, X. Manipulating IL-10 signalling blockade for better immunotherapy. *Cell Immunol.* **2015**, *293*, 126–129. [[CrossRef](#)]
178. Hausler, S.F.; Del Barrio, I.M.; Diessner, J.; Stein, R.G.; Strohschein, J.; Honig, A.; Dietl, J.; Wischhusen, J. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. *Am. J. Transl. Res.* **2014**, *6*, 129–139.
179. Stagg, J.; Divisekera, U.; McLaughlin, N.; Sharkey, J.; Pommey, S.; Denoyer, D.; Dwyer, K.M.; Smyth, M.J. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 1547–1552. [[CrossRef](#)]
180. Holmgaard, R.B.; Zamarin, D.; Munn, D.H.; Wolchok, J.D.; Allison, J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *J. Exp. Med.* **2013**, *210*, 1389–1402. [[CrossRef](#)]
181. Spranger, S.; Koblish, H.K.; Horton, B.; Scherle, P.A.; Newton, R.; Gajewski, T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. *J. Immunother. Cancer* **2014**, *2*, 3. [[CrossRef](#)] [[PubMed](#)]
182. Hong, R.; Zhou, Y.; Tian, X.; Wang, L.; Wu, X. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1(hi)breast cancer via enhancing immune cells activity. *Int. Immunopharmacol.* **2018**, *54*, 118–124. [[CrossRef](#)] [[PubMed](#)]
183. Suzuki, E.; Kapoor, V.; Jassar, A.S.; Kaiser, L.R.; Albelda, S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. *Clin. Cancer Res.* **2005**, *11*, 6713–6721. [[CrossRef](#)] [[PubMed](#)]
184. Sevko, A.; Michels, T.; Vrohings, M.; Umansky, L.; Beckhove, P.; Kato, M.; Shurin, G.V.; Shurin, M.R.; Umansky, V. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. *J. Immunol.* **2013**, *190*, 2464–2471. [[CrossRef](#)]
185. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rebe, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. *Cancer Res.* **2010**, *70*, 3052–3061. [[CrossRef](#)] [[PubMed](#)]

186. Eriksson, E.; Wenhe, J.; Irenaesus, S.; Loskog, A.; Ullenhag, G. Gemcitabine reduces MDSCs, tregs and TGFbeta-1 while restoring the teff/treg ratio in patients with pancreatic cancer. *J. Transl. Med.* **2016**, *14*, 282. [[CrossRef](#)]
187. Highfill, S.L.; Cui, Y.; Giles, A.J.; Smith, J.P.; Zhang, H.; Morse, E.; Kaplan, R.N.; Mackall, C.L. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci. Transl. Med.* **2014**, *6*, 237ra267. [[CrossRef](#)]
188. Sun, L.; Clavijo, P.E.; Robbins, Y.; Patel, P.; Friedman, J.; Greene, S.; Das, R.; Silvin, C.; Van Waes, C.; Horn, L.A.; et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. *J. CI Insight* **2019**, *4*. [[CrossRef](#)]
189. Qin, H.; Lerman, B.; Sakamaki, I.; Wei, G.; Cha, S.C.; Rao, S.S.; Qian, J.; Hailemichael, Y.; Nurieva, R.; Dwyer, K.C.; et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. *Nat. Med.* **2014**, *20*, 676–681. [[CrossRef](#)]
190. Scott, E.M.; Jacobus, E.J.; Lyons, B.; Frost, S.; Freedman, J.D.; Dyer, A.; Khaliq, H.; Taverner, W.K.; Carr, A.; Champion, B.R.; et al. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. *J. Immunother. Cancer* **2019**, *7*, 320. [[CrossRef](#)]
191. Cheng, P.; Eksioğlu, E.; Chen, X.; Wei, M.; Guenot, J.; Fox, J.; List, A.F.; Wei, S. Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro. *Blood* **2017**, *130*, 51. [[CrossRef](#)]
192. Jitschin, R.; Saul, D.; Braun, M.; Tohumeken, S.; Volkl, S.; Kischel, R.; Lutteropp, M.; Dos Santos, C.; Mackensen, A.; Mougiakakos, D. CD33/CD3-bispecific T-cell engaging (BiTE(R)) antibody construct targets monocytic AML myeloid-derived suppressor cells. *J. Immunother. Cancer* **2018**, *6*, 116. [[CrossRef](#)] [[PubMed](#)]
193. Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Seliger, B.; Ehninger, G.; Bachmann, M.P. Tregs activated by bispecific antibodies: Killers or suppressors? *Oncoimmunology* **2015**, *4*, e994441. [[CrossRef](#)]
194. Koristka, S.; Cartellieri, M.; Theil, A.; Feldmann, A.; Arndt, C.; Stamova, S.; Michalk, I.; Topfer, K.; Temme, A.; Kretschmer, K.; et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. *J. Immunol.* **2012**, *188*, 1551–1558. [[CrossRef](#)] [[PubMed](#)]
195. Kvarnhammar, A.M.; Veitonmaki, N.; Hagerbrand, K.; Dahlman, A.; Smith, K.E.; Fritzell, S.; von Schantz, L.; Thageson, M.; Werchau, D.; Smedenfors, K.; et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. *J. Immunother. Cancer* **2019**, *7*, 103. [[CrossRef](#)]
196. Dao, T.; Mun, S.S.; Scott, A.C.; Jarvis, C.A.; Korontsvit, T.; Yang, Z.; Liu, L.; Klatt, M.G.; Guerreiro, M.; Selvakumar, A.; et al. Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. *Oncoimmunology* **2019**, *8*, 1570778. [[CrossRef](#)]
197. Morse, M.A.; Hobeika, A.C.; Osada, T.; Serra, D.; Niedzwiecki, D.; Lyerly, H.K.; Clay, T.M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. *Blood* **2008**, *112*, 610–618. [[CrossRef](#)]
198. Onda, M.; Kobayashi, K.; Pastan, I. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 4575–4582. [[CrossRef](#)]
199. Jarnicki, A.G.; Lysaght, J.; Todryk, S.; Mills, K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. *J. Immunol.* **2006**, *177*, 896–904. [[CrossRef](#)]
200. Yano, H.; Thakur, A.; Tomaszewski, E.N.; Choi, M.; Deol, A.; Lum, L.G. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. *J. Transl. Med.* **2014**, *12*, 191. [[CrossRef](#)]
201. Tian, Y.; Li, Y.; Shao, Y.; Zhang, Y. Gene modification strategies for next-generation CAR T cells against solid cancers. *J. Hematol. Oncol.* **2020**, *13*, 54. [[CrossRef](#)] [[PubMed](#)]
202. Correnti, C.E.; Laszlo, G.S.; de van der Schueren, W.J.; Godwin, C.D.; Bandaranayake, A.; Busch, M.A.; Gudgeon, C.J.; Bates, O.M.; Olson, J.M.; Mehlin, C.; et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. *Leukemia* **2018**, *32*, 1239–1243. [[CrossRef](#)] [[PubMed](#)]
203. Liu, R.; Jiang, W.; Yang, M.; Guo, H.; Zhang, Y.; Wang, J.; Zhu, H.; Shi, R.; Fan, D.; Yang, C.; et al. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies. *J. Immunother.* **2010**, *33*, 500–509. [[CrossRef](#)] [[PubMed](#)]
204. Chiu, D.; Tavare, R.; Haber, L.; Aina, O.H.; Vazzana, K.; Ram, P.; Danton, M.; Finney, J.; Jalal, S.; Krueger, P.; et al. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. *Cancer Immunol. Res.* **2020**, *8*, 596–608. [[CrossRef](#)] [[PubMed](#)]
205. Dubrot, J.; Milheiro, F.; Alfaro, C.; Palazon, A.; Martinez-Forero, I.; Perez-Gracia, J.L.; Morales-Kastresana, A.; Romero-Trebejo, J.L.; Ochoa, M.C.; Hervas-Stubbs, S.; et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. *Cancer Immunol. Immunother.* **2010**, *59*, 1223–1233. [[CrossRef](#)] [[PubMed](#)]
206. Niu, L.; Strahotin, S.; Hewes, B.; Zhang, B.; Zhang, Y.; Archer, D.; Spencer, T.; Dillehay, D.; Kwon, B.; Chen, L.; et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. *J. Immunol.* **2007**, *178*, 4194–4213. [[CrossRef](#)]
207. Skokos, D.; Waite, J.C.; Haber, L.; Crawford, A.; Hermann, A.; Ullman, E.; Slim, R.; Godin, S.; Ajithdoss, D.; Ye, X.; et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. *Sci. Transl. Med.* **2020**, *12*. [[CrossRef](#)]

-
208. Daniel, P.T.; Kroidl, A.; Kopp, J.; Sturm, I.; Moldenhauer, G.; Dorken, B.; Pezzutto, A. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: Costimulation via CD28 prevents “veto” apoptosis of antibody-targeted cytotoxic T cells. *Blood* **1998**, *92*, 4750–4757. [[CrossRef](#)]
 209. Rossi, E.A.; Rossi, D.L.; Cardillo, T.M.; Chang, C.H.; Goldenberg, D.M. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-alpha. *Mol. Cancer Ther.* **2014**, *13*, 2341–2351. [[CrossRef](#)]
 210. Schmohl, J.U.; Felices, M.; Taras, E.; Miller, J.S.; Vallera, D.A. Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. *Mol. Ther.* **2016**, *24*, 1312–1322. [[CrossRef](#)]